Erlotinib HCl (OSI-744)

Name: Erlotinib HCl (OSI-744)
Brand: Selleck Chemicals
SKU: S1023
Rating: 5 (464 reviews)

For research use only.

Catalog No.S1023 Synonyms: CP358774, NSC 718781

464 publications

Erlotinib HCl (OSI-744) Chemical Structure

CAS No. 183319-69-9

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Selleck's Erlotinib HCl (OSI-744) has been cited by 464 publications

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Cell, 2019, 178(4):807-819.e21

PubMed: 31398338 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Gastroenterology, 2019, 156(6):1788-1804

PubMed: 30641053 ( click the link to review the publication )

Cell Metab, 2019, 30(3):525-538

PubMed: 31303424 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):807-822

PubMed: 30423298 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(1):91-106

PubMed: 28457749 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2013, 3(12):1404-15

PubMed: 24065731 ( click the link to review the publication )

Cell Metab, 2013, 17(6):1000-8

PubMed: 23707073 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Genet, 2012, 44(8):852-60

PubMed: 22751098 ( click the link to review the publication )

Sci Adv, 2021, 7(10)eabe8671

PubMed: 33658202 ( click the link to review the publication )

Nat Commun, 2021, 12(1):4789

PubMed: 34373451 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(19)e2019580118

PubMed: 33941693 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e202004229

PubMed: 33443570 ( click the link to review the publication )

Theranostics, 2021, 11(13):6632-6643

PubMed: 33995681 ( click the link to review the publication )

Cancer Res, 2021, canres.2276.2020

PubMed: 33685992 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Cell Rep, 2021, 34(3):108647

PubMed: 33472066 ( click the link to review the publication )

PLoS Biol, 2021, 19(6):e3000797

PubMed: 34061819 ( click the link to review the publication )
Cancer Lett, 2021, 507:40-54

PubMed: 33741422 ( click the link to review the publication )

Sci Signal, 2021, 14(683)eabd9943

PubMed: 34006609 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):113

PubMed: 33771199 ( click the link to review the publication )

Cancers (Basel), 2021, 13(10)2331

PubMed: 34066157 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1198

PubMed: 33801941 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009216

PubMed: 33481911 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):181

PubMed: 34282120 ( click the link to review the publication )

Cells, 2021, 10(4)716

PubMed: 33804833 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:634371

PubMed: 33777943 ( click the link to review the publication )

Pharmacol Res, 2021, 170:105701

PubMed: 34087353 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1853-1864

PubMed: 33410241 ( click the link to review the publication )

Front Oncol, 2021, 11:665045

PubMed: 34168988 ( click the link to review the publication )

J Virol, 2021, JVI0119521

PubMed: 34379506 ( click the link to review the publication )

J Cell Mol Med, 2021, 10.1111/jcmm.16555

PubMed: 33955688 ( click the link to review the publication )

J Transl Med, 2021, 19(1):91

PubMed: 33639987 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Cancer Res Treat, 2021, 10.4143/crt.2021.385

PubMed: 33940786 ( click the link to review the publication )

Exp Eye Res, 2021, S0014-4835(21)00251-7

PubMed: 34252414 ( click the link to review the publication )

Environ Toxicol, 2021, 10.1002/tox.23125

PubMed: 33734566 ( click the link to review the publication )

Onco Targets Ther, 2021, 14:3813-3820

PubMed: 34188489 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Anticancer Res, 2021, 41(3):1261-1269

PubMed: 33788717 ( click the link to review the publication )
Anticancer Res, 2021, 41(8):3741-3746

PubMed: 34281832 ( click the link to review the publication )

Exp Ther Med, 2021, 21(1):9

PubMed: 33235618 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):65

PubMed: 34267282 ( click the link to review the publication )

Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w

PubMed: 33686255 ( click the link to review the publication )

Oncol Lett, 2021, 21(1):44

PubMed: 33262836 ( click the link to review the publication )

Mol Ther Oncolytics, 2021, 20:364-372

PubMed: 33614917 ( click the link to review the publication )

Commun Biol, 2021, 4(1):834

PubMed: 34215850 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-00409-1

PubMed: 32958903 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1792

PubMed: 32286289 ( click the link to review the publication )

Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107840

PubMed: 32610141 ( click the link to review the publication )

Mucosal Immunol, 2020, 4

PubMed: 32132671 ( click the link to review the publication )

Oncogene, 2020, 39(15):3163-3178

PubMed: 32051553 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(1) pii: E173

PubMed: 31936715 ( click the link to review the publication )
Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):66

PubMed: 32552913 ( click the link to review the publication )

Cells, 2020, 17;9(4) pii: E1003

PubMed: 32316635 ( click the link to review the publication )

Cancer Discov, 2020, CD-19-1262

PubMed: 32513774 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19;molcanther10362019

PubMed: 32430488 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371586 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 11(19):5746-5757

PubMed: 32913468 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30257-7

PubMed: 33197651 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Eur J Pharm Biopharm, 2020, S0939-6411(20)30305-2

PubMed: 33068736 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0420

PubMed: 33028660 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:585292

PubMed: 33194732 ( click the link to review the publication )

Front Oncol, 2020, 10:1593

PubMed: 33014812 ( click the link to review the publication )

J Cell Sci, 2020, jcs.238840

PubMed: 32546532 ( click the link to review the publication )

J Cell Mol Med, 2020, 22

PubMed: 32441057 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(2)

PubMed: 31940844 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9307

PubMed: 33291316 ( click the link to review the publication )
Sci Rep, 2020, 13;10(1):4722

PubMed: 32170113 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):959

PubMed: 31969600 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.014960

PubMed: 33273014 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxins (Basel), 2020, 12(12)E753

PubMed: 33260619 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4453-4460

PubMed: 32606939 ( click the link to review the publication )

Mol Med, 2020, 26(1):66

PubMed: 32611363 ( click the link to review the publication )

BMC Cancer, 2020, 4;20(1):375

PubMed: 32366230 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0227261

PubMed: 31914141 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:10983-10994

PubMed: 33149613 ( click the link to review the publication )

Thorac Cancer, 2020, 11

PubMed: 32525282 ( click the link to review the publication )

Chin Med, 2020, 15:66

PubMed: 32612672 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Am Soc Nephrol, 2020, ASN.2019111215

PubMed: 32616537 ( click the link to review the publication )

Neurooncol Adv, 2020, 2(1):vdaa067

PubMed: 32642717 ( click the link to review the publication )

Cancer Metab, 2020, 8:19

PubMed: 32974013 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )
Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Oncotarget, 2020, 11(46):4224-4242

PubMed: 33245718 ( click the link to review the publication )

J Pharmacol Toxicol Methods, 2020, 106895

PubMed: 32629158 ( click the link to review the publication )

Pharmaceutics, 2020, 12(2)

PubMed: 32028611 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Gastroenterology, 2019, 156(6):1788-1804

PubMed: 30641053 ( click the link to review the publication )

Small, 2019, 15(33):e1900309

PubMed: 31245925 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2220-2231

PubMed: 30890618 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3341-3351

PubMed: 30796031 ( click the link to review the publication )

Clin Cancer Res, 2019, 1;25(19):5866-5877

PubMed: 31431454 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):211

PubMed: 31118055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Anal Chem, 2019, 91(15):10026-10032

PubMed: 31282657 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):282

PubMed: 30910997 ( click the link to review the publication )

Br J Cancer, 2019, 120(3):306-316

PubMed: 30585254 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )
Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1565-1576

PubMed: 31270152 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Oncogenesis, 2019, 8(12):70

PubMed: 31772161 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(4):1002-1012

PubMed: 30635434 ( click the link to review the publication )

Front Oncol, 2019, 9:461

PubMed: 31214503 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Sci Rep, 2019, 9(1):845

PubMed: 30696915 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2357

PubMed: 30787334 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Biol Chem, 2019, 294(27):10530-10543

PubMed: 31126985 ( click the link to review the publication )

J Biol Chem, 2019, 294(21):8336-8347

PubMed: 30979723 ( click the link to review the publication )

Stem Cells Int, 2019, 2019:4254759

PubMed: 30863451 ( click the link to review the publication )

Respir Res, 2019, 20(1):270

PubMed: 31791326 ( click the link to review the publication )

Mol Imaging Biol, 2019, 21(4):696-704

PubMed: 30377939 ( click the link to review the publication )

J Ethnopharmacol, 2019, 239:111928

PubMed: 31077779 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Dev Biol, 2019, 10.1016/j.ydbio.2019.10.006

PubMed: 31610144 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2729-2736

PubMed: 30854046 ( click the link to review the publication )
Am J Cancer Res, 2019, 9(12):2719-2729

PubMed: 31911857 ( click the link to review the publication )

Spectrochim Acta A Mol Biomol Spectrosc, 2019, 10.1016/j.saa.2019.117737

PubMed: 31757706 ( click the link to review the publication )

JCI Insight, 2019, 10.1172/jci.insight.127552

PubMed: 31237864 ( click the link to review the publication )

Immunity, 2018, 49(1):134-150

PubMed: 29958800 ( click the link to review the publication )

J Exp Med, 2018, 215(1):115-140

PubMed: 29191914 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

PLoS Biol, 2018, 16(9):e2006624

PubMed: 30261040 ( click the link to review the publication )

PLoS Biol, 2018, 16(12):e2006660

PubMed: 30543635 ( click the link to review the publication )

Cell Syst, 2018, 6(3):343-354

PubMed: 29428415 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4344-4359

PubMed: 29844121 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Mol Cancer, 2018, 17(1):50

PubMed: 29455661 ( click the link to review the publication )

Int J Cancer, 2018, 143(8):1994-2007

PubMed: 29756386 ( click the link to review the publication )

Int J Cancer, 2018, 142(1):156-164

PubMed: 28906000 ( click the link to review the publication )

Cancer Lett, 2018, 436:1-9

PubMed: 30118839 ( click the link to review the publication )

Cancer Lett, 2018, 434:152-159

PubMed: 30036610 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

J Pathol, 2018, 244(2):242-253

PubMed: 29160922 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):31

PubMed: 29458405 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):684

PubMed: 29880898 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):219

PubMed: 29440633 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2018, 11:455-467

PubMed: 29858080 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 12:817-828

PubMed: 30153566 ( click the link to review the publication )

Stem Cells, 2018, 36(8):1273-1285

PubMed: 29726088 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(3):957-971

PubMed: 29843133 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11):2297-2308

PubMed: 30093568 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):732-739

PubMed: 29467274 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

MAbs, 2018, 10(7):1003-1017

PubMed: 30130447 ( click the link to review the publication )

Cell Biol Toxicol, 2018, 34(6):459-469

PubMed: 29478126 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):2063-2073

PubMed: 29701925 ( click the link to review the publication )

Cancer Sci, 2018, 109(8):2391-2400

PubMed: 29927028 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(12):2419-2435

PubMed: 30662801 ( click the link to review the publication )

Oncogenesis, 2018, 7(4):36

PubMed: 29691367 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Lung Cancer, 2018, 122:44-53

PubMed: 30032844 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):6975-6983

PubMed: 29336487 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386292 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(6):3073-3085

PubMed: 29575527 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )
Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 29933569 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3317

PubMed: 29463831 ( click the link to review the publication )

J Biol Chem, 2018, 293(3):984-994

PubMed: 29191829 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Gene, 2018, 642:95-102

PubMed: 29133145 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1214

PubMed: 30483119 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 59(6):695-705

PubMed: 30011381 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:565-581

PubMed: 29606890 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:887-897

PubMed: 29740218 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30226590 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):527-538

PubMed: 29845246 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):249

PubMed: 29506489 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):191

PubMed: 29448920 ( click the link to review the publication )

Cancer Med, 2018, 7(1):208-218

PubMed: 29239135 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(5):829-838

PubMed: 30167846 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:5499-5508

PubMed: 30233210 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:3087-3100

PubMed: 29872320 ( click the link to review the publication )

Curr Cancer Drug Targets, 2018, 18(3):278-286

PubMed: 28359236 ( click the link to review the publication )
Biochem Biophys Res Commun, 2018, 502(1):110-115

PubMed: 29787755 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1292-1299

PubMed: 29885023 ( click the link to review the publication )

Mol Med Rep, 2018, 17(2):2509-2514

PubMed: 29207200 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(10):935-943

PubMed: 30074936 ( click the link to review the publication )

Acta Haematol, 2018, 140(1):30-39

PubMed: 30071517 ( click the link to review the publication )

Pharmazie, 2018, 73(11):630-634

PubMed: 30396380 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875309 ( click the link to review the publication )

Biologics, 2018, 12:75-86

PubMed: 30154647 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12020-12034

PubMed: 29552290 ( click the link to review the publication )

Nanomedicine (Lond), 2018, 13(10):1107-1120

PubMed: 29874151 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018, 9(79):34996-35007

PubMed: 30405889 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29568372 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(5):518-529

PubMed: 28414315 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Nat Commun, 2017, 8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1420

PubMed: 29127277 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )
Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Autophagy, 2017, 13(3):579-591

PubMed: 28103122 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(14):3769-3780

PubMed: 28174235 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2990-3000

PubMed: 28416483 ( click the link to review the publication )

Cancer Res, 2017, 77(2):579-589

PubMed: 27671677 ( click the link to review the publication )

J Control Release, 2017, 262:58-71

PubMed: 28694030 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.27388

PubMed: 28980940 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.33173

PubMed: 29087937 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.20444

PubMed: 28195529 ( click the link to review the publication )

Oncogene, 2017, 36(48):6747-6748

PubMed: 29188822 ( click the link to review the publication )

Oncogene, 2017, 36(47):6542-6554

PubMed: 28759046 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e2980

PubMed: 28796259 ( click the link to review the publication )

Cell Death Dis, 2017, 8(9):e3033

PubMed: 28880262 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):357-364

PubMed: 27913578 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Oncol, 2017, 11(8):1065-1077

PubMed: 28486761 ( click the link to review the publication )
Mol Oncol, 2017, 11(6):670-681

PubMed: 28388009 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):628-639

PubMed: 28306189 ( click the link to review the publication )

Radiother Oncol, 2017, 124(3):504-512

PubMed: 28823407 ( click the link to review the publication )

Cancer Sci, 2017, 108(1):53-60

PubMed: 27783866 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(7):915-928

PubMed: 28289161 ( click the link to review the publication )

Biochem Pharmacol, 2017, 143:129-139

PubMed: 28716728 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(11)

PubMed: 29156644 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28572590 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16763

PubMed: 29196706 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1669

PubMed: 28490807 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2602

PubMed: 28572590 ( click the link to review the publication )

Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1669

PubMed: 28490807 ( click the link to review the publication )

Clin Lung Cancer, 2017, 18(3):281-285

PubMed: 28038979 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(10)

PubMed: 28265001 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

Phytomedicine, 2017, 36:59-67

PubMed: 29157829 ( click the link to review the publication )

Int J Oncol, 2017, 50(6):2049-2058

PubMed: 28440469 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):915-926

PubMed: 28052650 ( click the link to review the publication )
Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Biosci Rep, 2017, 37(3)

PubMed: 28507201 ( click the link to review the publication )

Environ Toxicol, 2017, 32(5):1628-1636

PubMed: 28101945 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189087

PubMed: 29253018 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Clin Exp Nephrol, 2017, 10.1007/s10157-017-1386-9

PubMed: 28176019 ( click the link to review the publication )

Oncol Lett, 2017, 14(3):3445-3454

PubMed: 28927099 ( click the link to review the publication )

J Vis Exp, 2017, 126

PubMed: 28829429 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1:PO.16.00019

PubMed: 32913967 ( click the link to review the publication )

Gels, 2017, 3(3)

PubMed: 30920523 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(65):109068-109078

PubMed: 29312591 ( click the link to review the publication )

Oncotarget, 2017, 8(41):70736-70751

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98771-98781

PubMed: 29228726 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Cancer Metab, 2017, 5:6

PubMed: 28852500 ( click the link to review the publication )

Oncotarget, 2017, 8(13):20961-20973

PubMed: 28423495 ( click the link to review the publication )

Oncotarget, 2017, 8(62):105479-105491

PubMed: 29285266 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )
Oncotarget, 2017, 8(38):63014-63025

PubMed: 28968967 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93825-93838

PubMed: 29212192 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111333-111345

PubMed: 29340057 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73745-73756

PubMed: 29088741 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29163770 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Am Soc Nephrol, 2016, 27(10):3105-3116

PubMed: 27694161 ( click the link to review the publication )

PLoS Pathog, 2016,

PubMed: 27711202 ( click the link to review the publication )

Cell Death Dis, 2016,

PubMed: 27685624 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Sci Rep, 2016, 6:32809

PubMed: 27609096 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 48(5):1855-67

PubMed: 26936292 ( click the link to review the publication )

J Drug Target, 2016, 25(2):125-131

PubMed: 27633093 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )
Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )

Oncotarget, 2016, 8(52):89552-89565

PubMed: 29163770 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26551-66

PubMed: 27034169 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015,

PubMed: 26195767 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(30):9406-11

PubMed: 26170313 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2005

PubMed: 25744720 ( click the link to review the publication )

Cancer Prev Res (Phila), 2015, 8(9):765-76

PubMed: 26100522 ( click the link to review the publication )

Cell Rep, 2015, 11(1):98-110

PubMed: 25843712 ( click the link to review the publication )

Cell Death Differ, 2015, 22(5):801-14

PubMed: 25361079 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29483

PubMed: 25688715 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25659577 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.03.014

PubMed: 25779676 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26538233 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

J Biol Chem, 2015,

PubMed: 26152725 ( click the link to review the publication )

BMC Genomics, 2015, 16 Suppl 12:S2

PubMed: 26681397 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )
Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Cancer Chemoth Pharm, 2015, 10.1007/s00280-015-2751-6

PubMed: 25907508 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140782

PubMed: 26474061 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )

Anal Biochem, 2015, 10.1016/j.ab.2015.01.016

PubMed: 25659657 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9206-19

PubMed: 25826078 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14329-43

PubMed: 25869210 ( click the link to review the publication )

Oncotarget, 2015, 9(38):24914-24926

PubMed: 29861842 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26486084 ( click the link to review the publication )

J Hepatol, 2014, 60(1):143-51

PubMed: 23978713 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(13):3613-22

PubMed: 24803578 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(15):4047-58

PubMed: 24895459 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 10.1089/ars.2013.5304

PubMed: 24684506 ( click the link to review the publication )

Sci Signal, 2014, 7(338):ra75

PubMed: 25118327 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(9):2203-14

PubMed: 25028470 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):152-60

PubMed: 24954871 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

J Transl Med, 2014, 12(1):265

PubMed: 25240937 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):649-663

PubMed: ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 351(2):352-8

PubMed: 25187431 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

J Mol Endocrinol, 2014, 52(2):223-34

PubMed: 24463098 ( click the link to review the publication )

Oncol Res, 2014, 21(3):137-44

PubMed: 24512728 ( click the link to review the publication )

BMC Microbiol, 2014,

PubMed: 25471819 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Histochem Cell Biol, 2014, 10.1007/s00418-014-1223-0

PubMed: 24824474 ( click the link to review the publication )

Biores Open Access, 2014, 3(4):176-82

PubMed: 25126481 ( click the link to review the publication )
Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(24):6842-52

PubMed: 24130071 ( click the link to review the publication )

Cell Rep, 2013, 4(4):764-75

PubMed: 23972990 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

BRIT J CANCER, 2013, 109(8):2155-66

PubMed: 24045666 ( click the link to review the publication )

Lung Cancer, 2013, 81(3):354-61

PubMed: 23769318 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(1):864-70

PubMed: 23299479 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62104

PubMed: 23690929 ( click the link to review the publication )

Laser in Surg Med, 2013, 45(7):460-8

PubMed: 24037824 ( click the link to review the publication )

Head Neck, 2013, 35(1):86-93

PubMed: 22495823 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23896512 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

J Clin Invest, 2012, 122(9):3197-210

PubMed: 22886302 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Cancer, 2012, 118(21):5198-209

PubMed: 22510844 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(10):e48532

PubMed: 23119048 ( click the link to review the publication )

Oncogene, 2011, 30(22):2547-57

PubMed: 21278786 ( click the link to review the publication )
Mol Cancer Ther, 2011, 10(10):1846-56

PubMed: 21768330 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Microvasc Res, 2011, 81(1):135-42

PubMed: 21067705 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(4):577-86

PubMed: 20097731 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Case Western Reserve University, 2010, Zhang Z

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

Targets

HER1/EGFR ^[1]
(Cell-free assay)

2 nM

In vitro

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. ^[1] Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. ^[2] Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. ^[3] The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. ^[4] Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human SKBR3 cells	MoLuSpVv[3Srb36gZZN{[Xl?			MWHJcohq[mm2aX;uJI9nKEiHUkKgbY4hcHWvYX6gV2tDWjNiY3XscJMh[nliSGTSSkBie3OjeTygTWM2OD1zLki5JO69VS5?	NUnITIhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NVU1OTJpPkG5PFE2PDF{PD;hQi=>
human A431 cells	M3W3NWZ2dmO2aX;uJIF{e2G7			MUjJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{BjgSCKVGLGJIF{e2G7LDDJR\|UxRTBwNEKg{txONg>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQThzNUSxNkc,OTl6MUW0NVI9N2F-
A431	MV3GeY5kfGmxbjDhd5NigQ>?			MoLNTY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMh[nlicHjvd5Bpd3S7cn;zbY5mKEWOSWPBJIF{e2G7LDDJR\|UxKD1iMD6wNFEzKM7:TT6=	MlHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
MCF7	MoPTR5l1d3SxeHnjbZR6KGG\|c3H5			M{PwOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNuIFnDOVAhRSByLkCwNVIh\|ryPLh?=	MoPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
A431	NEPKbGFHfW6ldHnvckBie3OjeR?=		NX3qVZRSPjBibXnudy=>	MkTjTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKGGldHn2ZZRqd25iaX6gbJVu[W5iQUSzNUBk\WyuczDwdoV1emWjdHXkJIZweiB4MDDtbY5{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBidmRibXXhd5Vz\WRiYX\0[ZIhOTBibXnud{BjgSCHTFnTRUwhUUN3MDC9JFAvODBzMjFOwG0v	NVXX[IxLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVg5PjlpPkOwNFk5QDZ7PD;hQi=>
A431	Mn3QSpVv[3Srb36gZZN{[Xl?		Mn7sOlAhdWmwcx?=	MmmyTY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVITiCrbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBxemWrbnP1ZoF1\WRiZn;yJFYxKG2rboOg[o9tdG:5ZXSgZpkhTUeIIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDFyIH3pcpMh[nliRVzJV2EhdWW2aH;kMEBKSzVyIE2gNE4xODF{IN88UU4>	M3nTdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEm0OVg6Lz5{N{i5OFU5QTxxYU6=
A431	NH2wNJVHfW6ldHnvckBie3OjeR?=		NInEd5g3OCCvaX7z	M{TxcWlvcGmkaYTpc44hd2ZiRVfGVkBqdiCqdX3hckBCPDNzIHPlcIx{KGOxbYDveY5lKHC{ZYTy[YF1\WRiZn;yJFYxKG2rbjDi[YZwemViRVfGJJN1cW23bHH0bY9vKG[xcjCxNEBucW6\|IHL5JJBpd3OyaH;0fZJwe2mwZTDFUGlUSSCleYTvZoxwfCCvZYToc4QtKEmFNUCgQUAxNjByMUKg{txONg>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6MkWxPUc,OjV6OEK1NVk9N2F-
HCC827	MoLYR5l1d3SxeHnjbZR6KGG\|c3H5		M3nFbVQ5KGi{cx?=	Mor6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEQDJ5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjByMjFOwG0v	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEizNEc,OjR7MEC4N\|A9N2F-
PC9	MYTGeY5kfGmxbjDhd5NigQ>?		MkP2NkBpenN?	M4r6[mlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOgZYZ1\XJiMjDodpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wNFU6KM7:TT6=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|MEm5OEc,OjN7M{C5PVQ9N2F-
NCI-H292	NXfv[JI4TnWwY4Tpc44h[XO\|YYm=		MkX4NUBpeg>?	NHH0fGlKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJG5EUS2KMkmyJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBnd2yub4fl[EBjgSC\|dHnteYxifGmxbjD3bZRpKEWJRjDmc5IhQCCvaX7zJIJ6KGWuZXP0do9kcGWvaXz1cYlv\XOlZX70JIludXWwb3Hzd4F6NCCLQ{WwJF0hOC5yME[zJO69VS5?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NUmxPUc,OjZ2NUW5NVk9N2F-
HCC827	MWHGeY5kfGmxbjDhd5NigQ>?		NGHlb5EzKGi{cx?=	M3Pjd2lvcGmkaYTpc44hd2ZiRVfGVkBl\WyndHnvckBufXSjboSgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJS0N6MkegZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlAxQCEQvF2u	NFH5UFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
MCF7	NH7yO3VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWPub3FjPDhiaILz	NWLvd3BxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAyKM7:TT6=	M1LOfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUG0PFM4Lz5zOUmxOFg{PzxxYU6=
H3255	NGGwNoZHfW6ldHnvckBie3OjeR?=		NEjVPWozKGi{cx?=	M3HhVGlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6UjDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDIN\|I2PSClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGg{txONg>?	Mm\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H3255	NImxeoJHfW6ldHnvckBie3OjeR?=		M2TJe\|IhcHK\|	MlLLTY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUIH31eIFvfCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDN{NUWgZ4VtdHNicILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCHR1[gd5RqdXWuYYTpc44h\m:{IEGwJI1qdnNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCxJO69VS5?	MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEe3N\|AoRjJ6Mki3O\|MxRC:jPh?=
PC9	NUTBTmZFTnWwY4Tpc44h[XO\|YYm=		M1;mOFIhcHK\|	MUjJcohq[mm2aX;uJI9nKEWJRmKg[IVt\XSrb36gcZV1[W62IHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gVGM6KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IIPhcoR4cWOqIFXMTXNCNCCLQ{WwJF0hOC5yMUGg{txONg>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
A549	NHzpWo1HfW6ldHnvckBie3OjeR?=		MnzHNkBpenN?	M4L4bGlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQhf2muZD30fZBmKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG1OFkh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlAyOSEQvF2u	MonvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEe3N\|AoRjJ6Mki3O\|MxRC:jPh?=
PC9	MkT1SpVv[3Srb36gZZN{[Xl?		M4jGTVIhcHK\|	MWrJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFCFOTDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUCgcYlveyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGxJO69VS5?	M{TJWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
A549	MXLGeY5kfGmxbjDhd5NigQ>?			NH;wOIxKdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKHerbHSgeJlx\SCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCxNUDPxE1w	NWr2OpYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
BA/F3	M{nsfmN6fG:2b4jpZ4l1gSCjc4PhfS=>			MnHkR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCHR1\SJGw5PTiUIH31eIFvfCxiSVO1NEA:KDBwMEGyOUDPxE1w	MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{M{myNlkoRjF7MkO5NlI6RC:jPh?=
KB	MWLGeY5kfGmxbjDhd5NigQ>?		NEGzfYIyKGi{	MYjJcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiRVfGVkBqdiCqdX3hckBMSiClZXzsd{BqdmO3YnH0[YQh\m:{IEGgbJIheHKrb4KgeI8hTUeIIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB4IH3pcpMh[nliRVzJV2EtKEmFNUCgQUAxNjBzOTFOwG0v	MkW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUGxNlMoRjJ2NEGxNVI{RC:jPh?=
NIH3T3	NXnGdItbTnWwY4Tpc44h[XO\|YYm=			NEnYbpNKdmirYnn0bY9vKG:oIFXHSkB{fGmvdXzheIVlKGi3bXHuJIVz[kJzIHH1eI9xcG:\|cHjvdplt[XSrb36gbY4hVkmKM2SzJINmdGy\|LDDJR\|UxKD1iMD6wNVk{KM7:TT6=	NHrsXYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS4NFI5PCd-MU[0PFAzQDR:L3G+
MCF7	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{fhXlQ5KGi{cx?=	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEKg{txONg>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizOUc,OTl7MUS4N\|U9N2F-
Sf9	NX;kOFI2TnWwY4Tpc44h[XO\|YYm=			MnjZTY5pcWKrdHnvckBw\iClbH;u[YQhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjB{IN88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
MCF7	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVXUO\|JxPDhiaILz	NGHwVFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFIh\|ryPLh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODByNUGxOkc,OjByMEWxNVY9N2F-
MCF7	Mk\NRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYi0PEBpenN?	NGCxTlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFIh\|ryPLh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV7NEi1PUc,OjB3OUS4OVk9N2F-
MCF7	NFjzSVdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmDxOFghcHK\|	MmC0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5N{W4PEc,OjJ{N{e1PFg9N2F-
A16-F10	Mm\0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVK0PEBpenN?	M{X2b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUG2MWYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFzMkW0NUc,OjJzMUK1OFE9N2F-
MCF7	NX3CTpg4S3m2b4TvfIlkcXS7IHHzd4F6		NEDKWpg1QCCqcoO=	MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	MmnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEKyPVAoRjJzOECyNlkxRC:jPh?=
MCF7	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=		NIXKWGE1QCCqcoO=	MnnwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	NY[5eHgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2Nlc2QTdpPkKwOlI4PTl5PD;hQi=>
HT-29	M13RNGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml3FOFghcHK\|	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB{IN88UU4>	M2n6Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVU3Lz5{OUSwO\|k2PjxxYU6=
MCF7	Ml3ZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NUHBfI83PDhiaILz	M{TiT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
HCC827	NGq5U\|dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NIHxfVg4OiCqcoO=	MmTWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE4xOjlizszNMi=>	NFvtdGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4O\|kyPyd-Mk[0PFc6OTd:L3G+
Sf9	MVvGeY5kfGmxbjDhd5NigQ>?			NEPXR4pKdmirYnn0bY9vKG:oIHPsc45m\CCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44h\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzMYlv\mWldHXkJHNnQSClZXzsd{BjgSC\|b3zp[E1xcGG\|ZTDFUGlUSSxiSVO1NEA:KDBwMEOg{txONg>?	Mn;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUS4N\|UoRjF7OUG0PFM2RC:jPh?=
Sf9	NED2VVNHfW6ldHnvckBie3OjeR?=		MknvNUBpeg>?	NYrONVVCUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDIbZM3gC22YXfn[YQhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhOSCqcjDifUBGVEmVQTygTWM2OCB;IECuNFMh\|ryPLh?=	Mne1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3OUS4OVkoRjJyNUm0PFU6RC:jPh?=
Sf9	M2P4eWZ2dmO2aX;uJIF{e2G7		M33WdVEhcHJ?	M3r6RWlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIFXHSnIh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFTFUGZKSS:2aX3lMZJme2:udnXkJIZtfW:{aX3leJJ6KGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	NIC3SXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3O\|U5QCd-MkKyO\|c2QDh:L3G+
Sf9	MkXTSpVv[3Srb36gZZN{[Xl?		MofUNVAhdWmwcx?=	NUX6Z3A3UW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBifXSxcHjvd5Bpd3K7bHH0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFTFUGZKSS:WaX3lMXJme2:udnXkJGZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yMzFOwG0v	NFjxS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
Sf9	M1rpXGZ2dmO2aX;uJIF{e2G7		NHmxOlkyKGi{	NFXlfWJKdmirYnn0bY9vKG:oIHjpd5Rq\GmwZT30ZYdo\WRiaIXtZY4hemWlb33ibY5idnRiY4n0c5Bt[XOvaXOg[I9u[WmwIH;mJGVITlJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBU\jliY3XscJMh[W[2ZYKgNUBpeiCkeTDESWxHUUFxdHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkCzJO69VS5?	M4DmZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{[xNlczLz5{MkO2NVI4OjxxYU6=
Sf9	MnjrSpVv[3Srb36gZZN{[Xl?		M1TMeVEhcHJ?	MV7Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFXHSnIh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFTFUGZKSS:2aX3lMZJme2:udnXkJIZtfW:{aX3leJJ6KGG\|c3H5MEBKSzVyIE2gNE4xOyEQvF2u	NYXQOVZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OlMyPDhpPkKxO\|Y{OTR6PD;hQi=>
Sf9	MkfVSpVv[3Srb36gZZN{[Xl?		MkSyNUBpeg>?	NIHYe\|ZKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgSWdHWiCneIDy[ZN{\WRiaX6gbY5{\WO2IGPmPUBk\WyuczDh[pRmeiBzIHjyJIJ6KHSrbXWtdoV{d2y4ZXSg[ox2d3KrbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMzFOwG0v	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzNkWxO{c,OjF6MU[1NVc9N2F-
Sf9	NWS1S3BOTnWwY4Tpc44h[XO\|YYm=			MYLJcohq[mm2aX;uJI9nKGirc4Tp[Ilv\S22YXfn[YQhemWlb33ibY5idnRiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjB\|IN88UU4>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{N{W5O{c,OjB4Mke1PVc9N2F-
MIAPaCa2	MlXZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1HUZVQ5KGi{cx?=	M3;xVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIF3JRXBiS2F{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFMh\|ryPLh?=	NGrK[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k2Pid-Mkm0NFc6PTZ:L3G+
MCF7	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVLqdopiPDhiaILz	NVzBWm1ZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCzJO69VS5?	NUfoclJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PTZpPkK5OFA4QTV4PD;hQi=>
PC3	M2P6c2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUS0PEBpenN?	M1\IUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	NHrIVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k2Pid-Mkm0NFc6PTZ:L3G+
Sf9	NHjQV3lHfW6ldHnvckBie3OjeR?=			MkLoTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKHKnY3;tZolv[W62IFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCijbXnuc{Bi[2mmczC2OFUuOTF6NjmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBmdnq7bXWgZZV1d3Cqb4PwbI9zgWyjdHnvckBjgSCGRVzGTWEwfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvODNizszNMi=>	NHO4VoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlQzOSd-MkWxO\|I1OjF:L3G+
Sf9	NWrvUFV1TnWwY4Tpc44h[XO\|YYm=			NH;Sb3RKdmirYnn0bY9vKG:oIFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCijbXnuc{Bi[2mmczC2OFUhfG9iMUG4OkkhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCnbor5cYUh[XW2b4Doc5NxcG:{eXzheIlwdiCkeTDESWxHUUFidHnt[UBz\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMEOg{txONg>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUW3NEc,OjN{NEW1O\|A9N2F-
A549	NFzJS\|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmqyNlQhcHK\|	NITP[FRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygS2k2OCB;IECuNFMh\|ryPLh?=	MmntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OUGzOlQoRjJ\|M{mxN\|Y1RC:jPh?=
Sf9	NUnod\|hTTnWwY4Tpc44h[XO\|YYm=		NGDne4syOCCvaX7z	M{\GNGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCtaX7hd4Uh[3m2b4DsZZNucWNiZH;tZYlvKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIV5eHKnc4Ppc44hfmWldH;yMYlv\mWldHXkJIlve2WldDDz[lkh[2WubIOgZZN{\XO\|ZXSgZZMhdGW4ZXygc4Yh[XW2b4Doc5NxcG:{eXzheIlwdiCjZoTldkAyOCCvaX7zJIJ6KESHTF\JRU91cW2nLYLld49tfmWmIH\seY9zd22ndIL5MEBKSzVyIE2gNE4xOyEQvF2u	Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK2OlAoRjJ\|OU[yOlYxRC:jPh?=
NCI-H292	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUC3NkBpenN?	MkD0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFI6OiClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHR1\SJIFnfGW{IEeyJIhzeyCkeTDseY1qdmW\|Y3XuZ4Uh[XO\|YYmsJGVEPTBiPTCwMlA{OSEQvF2u	M2rVZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEW1PVE6Lz5{NkS1OVkyQTxxYU6=
Sf9	M37OOmZ2dmO2aX;uJIF{e2G7		NIDRRlMyKGi{	M{TiUGlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApPjR3IITvJFEyQDZrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFTFUGZKSS:2aX3lMZJme2:udnXkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMEOyJO69VS5?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{m5PEc,OjR4MEe5PVg9N2F-
Sf9	NH\4cYdHfW6ldHnvckBie3OjeR?=		NWLN[nVXOSCqch?=	MX3Jcohq[mm2aX;uJI9nKGG3dH;wbI9{eGixconsZZRqd25ib3[gSWdHWiCleYTvdIxie22rYzDkc41icW5iKHHtbY5wKGGlaXTzJFY1PSC2bzCxNVg3MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yM{Kg{txONg>?	NVHnbnZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|A1OTJpPkK0OlMxPDF{PD;hQi=>
Sf9	NFjWNYhHfW6ldHnvckBie3OjeR?=		NFXTbGUyOCCvaX7z	NFHT[WdKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDi2OFUhfG9iMUG4OkkhMHWwa37ve44hd3KrZ3nuLUBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDmc4xtd3enZDDifUBCXFBvTXfDcFIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgNUBpeiCkeTDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAxNjB\|MjFOwG0v	MoPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNES4OVQoRjJ2MUS0PFU1RC:jPh?=
A431	MnvuSpVv[3Srb36gZZN{[Xl?			NUL5ZnhlUW6qaXLpeIlwdiCxZjDFS2ZTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTBiPTCwMlA{PCEQvF2u	NELqPJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OlY2PSd-MkCzOFY3PTV:L3G+
A549	MoqxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHrCfZI1QCCqcoO=	M4[5OmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5yNDFOwG0v	Mn;FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OVYoRjJ7NEC3PVU3RC:jPh?=
B16/F10	NXzV[VdKSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYC0PEBpenN?	NUHpV25[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVYwTjFyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB3IN88UU4>	M{C2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkS1PFAzLz5{M{K0OVgxOjxxYU6=
MIAPaCa	NH[1WWNHfW6ldHnvckBie3OjeR?=			M2LDWmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUWlCWGGFYTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMEWxJO69VS5?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODhzN{WyN{c,OjB6MUe1NlM9N2F-
A431	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		M{jsSlQ5KGi{cx?=	NFnBcpJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYKg[ZhxemW\|c3nu[{BGT0[UIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC1OUDPxE1w	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRzNE[xNkc,OjJ2MUS2NVI9N2F-
Sf9	M2T6R2Z2dmO2aX;uJIF{e2G7			NEX6UpRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIZ2dGxvbHXu[5RpKEeVVD30ZYdo\WRiaIXtZY4hSi2UQV[gWlYxOEVibYX0ZY51KCh2MUegeI8hPzZ4IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hSmGldXzveolzfXNiaX7m[YN1\WRiU3[5JINmdGy\|IIXzbY5oKE5vdHXycYlv[WxiSHnzMZRi\2enZDDoeY1idiCPRVuxJIF{KHO3YoP0doF1\SCkeTDOeU1x[WenIHflcE1j[XOnZDDwbI9{eGixcjDzZ5Jm\W5iYX7hcJl{cXNuIFnDOVAhRSByLkC2JO69VS5?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2OUi0NUc,Ojl3NEm4OFE9N2F-
Sf9	NHK4[ZdHfW6ldHnvckBie3OjeR?=		MknMNVAhdWmwcx?=	NXzhW5pIUW6qaXLpeIlwdiCxZjDIbZM3NXSjZ3fl[EBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApfW6tbn;3ckBwemmpaX6pJEg3PDVidH:gNVE5PiC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoLUmgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzMDDtbY5{KG[xbHzve4VlKGK7IFHUVEBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFTFUGZKSS:WaX3lMXJme2:udnXkJIZtfW:{b33leJJ6NCCLQ{WwJF0hOC5yNjFOwG0v	NGO0d2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM2Oyd-Mki0N\|E{PTN:L3G+
MCF7	M3\IN2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYK0PEBpenN?	NFXIV2VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFch\|ryPLh?=	NXTxd3pKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
PC9	M1;qVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWG5OkBpenN?	NXK2bHJMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|kh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IGP5eI95KGe{ZXXuJI1iemuncjDiZZNm\CCobIXvdoV{[2WwY3WgZY5idHm\|aYOsJGlEPTBiPTCwMlA4KM7:TT6=	NUfnV3NZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PVk2OzJpPkK2OVk6PTN{PD;hQi=>
LoVo	MYHGeY5kfGmxbjDhd5NigQ>?		MXGyJIhzew>?	NFrmfpFKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBNd1[xIHPlcIx{KGGodHXyJFIhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODd5IN88UU4>	NXTJSJpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|A6QTRpPkKzPVMxQTl2PD;hQi=>
HepG2	MmO0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIXG[VI1QCCqcoO=	MkizRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wPEDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzNkWxO{c,OjF6MU[1NVc9N2F-
MCF7	Mk\LRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MoDwOFghcHK\|	M37OUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wPEDPxE1w	MmXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7OEi2NlQoRjJ6OUi4OlI1RC:jPh?=
Sf9	MUXGeY5kfGmxbjDhd5NigQ>?		NVeyPJBGOTBibXnudy=>	M1zsR2lvcGmkaYTpc44hd2ZiSHnzOk11[WepZXSgSWdHWiBqdX7rco94diCxcnnnbY4qKGO7dH;wcIF{dWmlIHTvcYFqdiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{Bi\nSncjCxNEBucW6\|IH\vcIxwf2WmIHL5JIFl\Gm2aX;uJI9nKEGWUD3N[2NtOiCjbnSgcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMEig{txONg>?	NFPLdpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k2Pid-Mkm0NFc6PTZ:L3G+
Sf9	M3T5VGZ2dmO2aX;uJIF{e2G7			MUnJcohq[mm2aX;uJI9nKEircz22JJRi\2enZDDy[YNwdWKrbnHueEBGT0[UIHP5eI9xdGG\|bXnjJIRwdWGrbjCoOlQ2KHSxIEGxPFYhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSClZXzsd{BjgSCmaYPzc4Nq[XSrb36t[Y5p[W6lZXSgcIFvfGijbnnk[UBndHWxcnXzZ4Vv[2ViaX3teY5w[XO\|YYmveIlu\S2{ZYPvcJZm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCwMlA5KM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2OUi0NUc,Ojl3NEm4OFE9N2F-
MCF7	MkfBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHnxT2czPCCqcoO=	MkTuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC4JO69VS5?	M2fzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{mxN\|Y1Lz5{M{O5NVM3PDxxYU6=
BA/F3	MnXHSpVv[3Srb36gZZN{[Xl?		Mn\FOFghcHK\|	MYPJcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBKSzVyIE2gNE4xQDdizszNMi=>	NUL4V3hvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|U5PDFpPkK3NlM2QDRzPD;hQi=>
Sf9	MmHESpVv[3Srb36gZZN{[Xl?		MoHEOUBucW6\|	MnvpTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCJU2SteIFo\2WmIFjFVlIhMDZ5Nj3lcoQqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgOUBucW6\|IH\vcIxwf2WmIHL5JGFVWCCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiM{CgcYlveyCkeTDIWHJHKGG\|c3H5MEBKSzVyIE2gNE4xQTFizszNMi=>	M17qdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm2OVgxLz5\|MEC5OlU5ODxxYU6=
A431	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		MkPnO\|IhcHK\|	NX22bGlyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yOU[g{txONg>?	NGjhbo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUi4PFc3OSd-MUm4PFg4PjF:L3G+
B16F10	NUT0WHFNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MW[0PEBpenN?	NVvBO3dOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOSEQvF2u	NGDhOZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2NVI4Oid-MkKzOlEzPzJ:L3G+
MCF7	M{HDVWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mo\JNVIhcHK\|	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhOTJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMTFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
A549	M4Dn[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGrHS3Y1QCCqcoO=	NWrrOnFwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF5MkSyNUc,OjVzN{K0NlE9N2F-
HepG2	NXvH[odDSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NW\XRYZSPDhiaILz	NWDOcnJ4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yKM7:TT6=	M4jXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOFIyLz5{NUG3NlQzOTxxYU6=
Sf9	MnHTSpVv[3Srb36gZZN{[Xl?			NGnqbnZKdmirYnn0bY9vKG:oIHj1cYFvKGOub37l[EBJTVJ{IHH1eI9xcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|LXnu[oVkfGWmIGPmPUBk\WyuczDifUB{d2yrZD3wbIF{\SCHTFnTRUwhUUN3MDC9JFAvOTJizszNMi=>	NY[0OHI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVQ5OzdpPkG5PVE1QDN5PD;hQi=>
HepG2	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVrzZmxMPDhiaILz	M2fHcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVIh\|ryPLh?=	NYn0epVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNVI2PDFpPkKyNVEzPTRzPD;hQi=>
B16F10	MljwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MlroOFghcHK\|	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEJzNl[xNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl6OE[yOEc,Ojh7OEi2NlQ9N2F-
HepG2	Ml\ORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Ml:1OFghcHK\|	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{m5PEc,OjR4MEe5PVg9N2F-
HepG2	NVLQc3F[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUnqRpZoPDhiaILz	Mln0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	MmjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{C0NVIoRjJ2NkOwOFEzRC:jPh?=
HepG2	M3nUVmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVW0PEBpenN?	MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMjFOwG0v	MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNES4OVQoRjJ2MUS0PFU1RC:jPh?=
HepG2	NVXDZ4prSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1yxbFEzKGi{cx?=	NUC2e2NkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjCxNkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	NX;5R5d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI1QDJpPkK2OlUzPDh{PD;hQi=>
HepG2	NIDaN3FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYq0PEBpenN?	NVrLUGhxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	NVLWW281RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOFU2PzBpPkKzNlQ2PTdyPD;hQi=>
HepG2	M{POcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkjVOFghcHK\|	NX\SVmVMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	NGnkNYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2NlY3OCd-MkO5OlI3PjB:L3G+
U251	MlGwSpVv[3Srb36gZZN{[Xl?			M2nYRmlvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIHj1cYFvKFV{NUGgZ4VtdHNiYomgdIhwe3Cqb4T5do9{cW6nIFXMTXNCKGG\|c3H5MEBKSzVyIE2gNE4yOjR5IN88UU4>	M3vDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEmwOlUzLz5{NEi5NFY2OjxxYU6=
U251	NV;oc\|RKTnWwY4Tpc44h[XO\|YYm=		NWDpN3FlPjBibXnudy=>	Ml3qTY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgWmVITlJ{IHHjeIl3[XSrb36gbY4hcHWvYX6gWVI2OSClZXzsd{BxemW2cnXheIVlKG[xcjC2NEBucW6\|IH\vcIxwf2WmIHL5JHZGT0ZiYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEGwJI1qdnNiYomgSWxKW0FuIFnDOVAhRSByLkGyOFch\|ryPLh?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
U251	MUnGeY5kfGmxbjDhd5NigQ>?		MWW2NEBucW6\|	MVXJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCqdX3hckBWOjVzIHPlcIx{KGOxbYDveY5lKHC{ZYTy[YF1\WRiZn;yJFYxKG2rbjDi[YZwemViVlXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiY4n0c4Jtd3RibXX0bI9lNCCLQ{WwJF0hOC5zMkS3JO69VS5?	NV3L[mI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFI2OTlpPkK1PFgzPTF7PD;hQi=>
A549	NHG0RYZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXXwTpBZPDhiaILz	NVroOG9mSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE{KM7:TT6=	M1HwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkC3PVk5Lz5{NE[wO\|k6QDxxYU6=
A549	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEDkcG01QCCqcoO=	M{fLZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xN{DPxE1w	NVLuT2tTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|A1OTJpPkK0OlMxPDF{PD;hQi=>
A549	NITVdGhEgXSxdH;4bYNqfHliYYPzZZk>		NW\DZYZuPDhiaILz	MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF\|IN88UU4>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2NEi1OEc,OjRzNES4OVQ9N2F-
A549	M4q5UmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MX60PEBpenN?	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUOg{txONg>?	NXXSXFVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlI3PjBpPkKzPVYzPjZyPD;hQi=>
HCT116	NULo[GJ6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYG0PEBpenN?	MkTWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVQh\|ryPLh?=	NWmxeFl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
DIFI	NWm3OHl2S3m2b4TvfIlkcXS7IHHzd4F6		MUC0JIRigXN?	MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDETWZKKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IECuNVQh\|ryPLh?=	NFHxe3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
Sf9	MV7GeY5kfGmxbjDhd5NigQ>?		NXXleoxuOSCqch?=	M{Tp[2lvcGmkaYTpc44hd2ZiaHnzeIllcW6nLYTh[4dm\CCqdX3hckBz\WOxbXLpcoFvfCCleYTvdIxie22rYzDkc41icW5ib3[gTGVTOiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFTFUGZKSS:2aX3lMZJme2:udnXkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMUSg{txONg>?	Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NkGyO\|IoRjJ{M{[xNlczRC:jPh?=
Sf9	MXXGeY5kfGmxbjDhd5NigQ>?			M3GxV2lvcGmkaYTpc44hd2ZiaIXtZY4h[2yxbnXkJGhGWjJiYYX0c5Bpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU3[5JINmdGy\|IHL5JJNwdGmmLYDoZZNmKEWOSWPBMEBKSzVyIE2gNE4yPiEQvF2u	NIfydYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxOFg{PSd-MUm5NVQ5OzV:L3G+
Sf9	MUfGeY5kfGmxbjDhd5NigQ>?		MVixJIhz	MWXJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEirc{\4MZRi\2enZDDISXIzKGG3dH;wbI9{eGixconsZZRqd25iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFXMTXNCNCCLQ{WwJF0hOC5zNjFOwG0v	M{mzXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm0PFU6Lz5{MEW5OFg2QTxxYU6=
Sf9	MV3GeY5kfGmxbjDhd5NigQ>?		MXqxJIhz	NUDkcHNtUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKGi3bXHuJGhGWjJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PzZidH:gNVI1PSliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nlidHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMU[g{txONg>?	MmnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{C0NVIoRjJ2NkOwOFEzRC:jPh?=
Sf9	M1zLRWZ2dmO2aX;uJIF{e2G7			MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGhGWjJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PzZidH:gNVI1PSliZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCGRVzGTWEhfGmvZTDy[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvOTZizszNMi=>	NGfnNGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K0OVgxOid-MkOyOFU5ODJ:L3G+
B16F10	MlHxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Moe1NVIhcHK\|	MnfvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEMU\GNVAh[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVch\|ryPLh?=	NWTxXFJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI1QDJpPkK2OlUzPDh{PD;hQi=>
HeLa	NHr0XnpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnfnNVIhcHK\|	Mn;vRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZVzhJINmdGy\|IHHmeIVzKDF{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkKg{txONg>?	MkHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK0PFIoRjJ4NkWyOFgzRC:jPh?=
Sf9	MX\GeY5kfGmxbjDhd5NigQ>?			NYHMWZVvUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIILlZ49u[mmwYX70JGhGWjJiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDlcpp6dWViYYX0c5Bpd3OyaH;yfYxifGmxbjDifUBFTUyISVGveIlu\S2{ZYPvcJZm\CCobIXvdo9u\XS{eTygTWM2OCB;IECuNkDPxE1w	NWH2N5JrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxO\|I1OjFpPkK1NVczPDJzPD;hQi=>
A16-F10	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHLIXYc1QCCqcoO=	M3zmc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUG2MWYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4zKM7:TT6=	M{TEcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkS1OVcxLz5{M{K0OVU4ODxxYU6=
MDA-MB-468	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=			NHftb3NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB1emmybHWgcoVo[XSrdnWgUWRCNU2ELUS2PEBk\WyuczygTWM2OCB;IECuNlM2OiEQvF2u	NVT0dpFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
CAL27	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		MmLXOEBl[Xm\|	M{TlSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNCVDJ5IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvOjN7IN88UU4>	M2DvNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
Sf9	MkDTSpVv[3Srb36gZZN{[Xl?		MkP3OUBucW6\|	MlOzTY5pcWKrdHnvckBw\iCJU2SteIFo\2WmIILlZ49u[mmwYX70JIh2dWGwIG\FS2ZTKCh5OEmt[Y5lMSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFUhdWmwczDmc4xtd3enZDDifUBCXFBiYXTkbZRqd25iYX7kJI1m[XO3cnXkJIFnfGW{IEOwJI1qdnNiYomgTHRTTiCjc4PhfUwhUUN3MDC9JFAvOjVizszNMi=>	M3KyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEm2OVgxLz5\|MEC5OlU5ODxxYU6=
A549	NV\qdJZnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWW0PEBpenN?	MmPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHX4dJJme3OrbnegSWdHWiCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGKjc3HsJINmdGxiZ4Lve5RpKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjJ5IN88UU4>	NY\6TpU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3OlMyPDhpPkKxO\|Y{OTR6PD;hQi=>
T24 NIH	NFjMeYhHfW6ldHnvckBie3OjeR?=			NI[1[JJKdmirYnn0bY9vKG:oIHzp[4Fv\CC\|dHnteYxifGWmIHXyZmIzKGG3dH;wbI9{eGixconsZZRqd25iaX6gWFI1KE6LSDDj[YxteyxiSVO1NEA:KDBwMkm5JO69VS5?	NVHLPYoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0PFAzQDRpPkG2OFgxOjh2PD;hQi=>
GXF251L	NFjTSWJEgXSxdH;4bYNqfHliYYPzZZk>		MVW0JIRigXN?	M4DmVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGdZTjJ3MVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5\|Nkmg{txONg>?	M{HoOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
A431	NWTRPGx5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1Lsc\|czKGi{cx?=	M3;INWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD60NFkh\|ryPLh?=	NXy1TmF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFM4PDJpPkK0NVg{PzR{PD;hQi=>
MDA-MB-231	NYO0SYVHS3m2b4TvfIlkcXS7IHHzd4F6			NWT5fJQ{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHKrcHzlJI5m\2G2aY\lJG1FSS2PQj2yN\|Eh[2WubIOsJGlEPTBiPTCwMlQ{QDVizszNMi=>	NWXKPZZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
A431	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUi3NkBpenN?	MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhT0l3MDC9JFAvPDdizszNMi=>	NHTFSm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m4N\|c1PSd-MUe5PFM4PDV:L3G+
BA/F3	M4TEU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHvhSok6PiCqcoO=	NX;mfGNYT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKESnbEGgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	NVzLeJU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
BA/F3	MlqxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{\pcVk3KGi{cx?=	MYLHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgSIVtOyCvdYThcpQh[W[2ZYKgPVYhcHK\|IHL5JINmdGxidHn0[ZIu\2yxIHHzd4F6NCCJSUWwJF0hOC53IN88UU4>	NE\wXYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKyNlc{Oyd-MkCyNlI4OzN:L3G+
BA/F3	NVPk[m9KT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYK5OkBpenN?	NIX4[nVIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTGWuNTDteZRidnRiYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDHTVUxKD1iMD61JO69VS5?	MojCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{MkK3N\|MoRjJyMkKyO\|M{RC:jPh?=
BA/F3	NV7zeW8yT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYq5OkBpenN?	M2XDN2dzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6UjDteZRidnRiYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDHTVUxKD1iMD61JO69VS5?	NWrGO\|RoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
Huh7.5	M2C2NmFvfGm4aYLhcEBie3OjeR?=		MmrEO\|IhcHK\|	NX\BeJZESW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdwNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKG2nYYP1doVlKGGodHXyJFczKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkWg{txONg>?	M{OwNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEKyO\|M6Lz5{NUiyNlc{QTxxYU6=
Huh7.5	MXLBcpRqfmm{YXygZZN{[Xl?		Mn;tO\|IhcHK\|	NWfXUZZISW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIVt\WO2cn;wc5JifGWmIHnuJIh2dWGwIFj1bFcvPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIlvfHKjY3XscJVt[XJiaX7m[YN1cX[rdImg[JJ2\yC2cnXheIVlKGW4ZYL5JFI1KGi{czDmc5IhPzJiaILzJI1m[XO3cnXkJFczKGi{czDwc5N1KGWuZXP0do9xd3KjdHnvckBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlUh\|ryPLh?=	NUDm[HBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NlI4OzlpPkK1PFIzPzN7PD;hQi=>
Huh7.5	MX\BcpRqfmm{YXygZZN{[Xl?		M2LMOVczKGi{cx?=	Moj5RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTIVx[XSrdHnzJGMhfmm{dYOgTlYwUk[KIHnu[oVkfGWmIHnuJIh2dWGwIFj1bFcvPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIV5fHKjY3XscJVt[XJiaX7m[YN1cX[rdImg[JJ2\yC2cnXheIVlKGW4ZYL5JFI1KGi{czDmc5IhPzJiaILzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjVizszNMi=>	NHLjPVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiyNlc{QSd-MkW4NlI4Ozl:L3G+
HEK293	M2Phc2Z2dmO2aX;uJIF{e2G7		M4TqVVUhdWmwcx?=	MYHJcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAzSjFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHs{UF2HM2OgeZB1[WunIHnuZ5Vj[XSnZDDmc5IhPSCvaX7zJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGtqKD1iMD61N{DPxE1w	Mm\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293	NH\WeFdHfW6ldHnvckBie3OjeR?=		M3S0RlUhdWmwcx?=	Mnn2TY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROkJzIHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBcO0ifRUPTJJVxfGGtZTDpcoN2[mG2ZXSg[o9zKDVibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBKSzVyIE2gNE42PSEQvF2u	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2MUC2PEc,OjJ3NEGwOlg9N2F-
A431	NGTIO3NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3m1fVczKGi{cx?=	NVv3emc2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjV4IN88UU4>	NXjHfFFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlU6PjlpPkK0OVY2QTZ7PD;hQi=>
MDA-MB-435	M3\LUmN6fG:2b4jpZ4l1gSCjc4PhfS=>			MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy\|LDDJR\|UxKD1iMD62NlIyKM7:TT6=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh7ME[1Nkc,OjR6OUC2OVI9N2F-
LXFA 629L	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		NELp[o81KGSjeYO=	M3LuN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNkK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLk[2JO69VS5?	NETNUow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
A549	M{K2VGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkDJNlQhcHK\|	NGT5c4dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjd\|IN88UU4>	M3G2clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEK4OVM1Lz5{OUCyPFU{PDxxYU6=
A431	NGr5UnFEgXSxdH;4bYNqfHliYYPzZZk>		NYHSNGpNPzJiaILz	MkDuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuO\|Uh\|ryPLh?=	NIHtb\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
A431	NUPqVWh6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVnGSI0zPzJiaILz	NYf0bFQ2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2suQCCjc4PhfUwhUUN3MDC9JFAvQDR2IN88UU4>	MmS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2OEe5NVcoRjJ4NEi3PVE4RC:jPh?=
A431	M3\HbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEnFSVA4OiCqcoO=	MmDDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUTVyIE2gNE46OTVizszNMi=>	NEXINlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm2PVQ3PSd-MUm5Olk1PjV:L3G+
Calu3	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		NI\CeI04OiCqcoO=	MnjzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FtfTNiY3XscJMh\XiycnXzd4lv\yCKRWKyJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlk{KM7:TT6=	MlrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUGxNlMoRjJ2NEGxNVI{RC:jPh?=
DU145	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=		MXS0JIRigXN?	M{DRcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvQTZ4IN88UU4>	M{TuelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
NCI-H2122	M{DFfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7			M2TDdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOTJ{IHPlcIx{NCCLQ{WwJF0hOSEQvF2u	NXH1V2RTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
NCI-H292	NVG5O2NzS3m2b4TvfIlkcXS7IHHzd4F6		MVS3NkBpenN?	M4PBfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMkmyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSBzIN88UU4>	M1GzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG1PFU3Lz5{NUKxOVg2PjxxYU6=
A431	MV;GeY5kfGmxbjDhd5NigQ>?		MXqxNEBucW6\|	MWXJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZYZ1\XJiMUCgcYlveyCkeTDGUGlUSSxiSVO1NEA:KDFwMjFOwG0v	NVLvUpVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFM4ODBpPkKwOFA{PzByPD;hQi=>
A431	NHzFeFdHfW6ldHnvckBie3OjeR?=			NIP4NXBKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGmwIHj1cYFvKEF2M{GgZ4VtdHNuIFnDOVAhRSBzLkKg{txONg>?	MlXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NUiwO\|IoRjJyNUW4NFczRC:jPh?=
A431	MU\GeY5kfGmxbjDhd5NigQ>?		NXPB[IpNPjBibXnudy=>	NX\Nb3NkUW6qaXLpeIlwdiCxZjDFS2ZTKHS7cn;zbY5mKGurbnHz[UBi[3Srdnn0fUBqdiCHR1[td5RqdXWuYYTl[EBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IE[wJI1qdnNiYomgSWxKW0FuIFnDOVAhRSBzLkKg{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyNEe0NUc,OjJ{MES3OFE9N2F-
A431	M{L1OGZ2dmO2aX;uJIF{e2G7		M3fwclYxKG2rboO=	MlfYTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBCPDNzIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJicILleJJm[XSnZDDmc5IhPjBibXnud{BxemmxcjD0c{BGT0ZiYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOTBibXnud{BjgSCyaH;zdIhwfHm{b4PpcoUhTUyLU1GgZ5l1d2Kub4SgZY5idHm\|aYOsJGlEPTBiPTCxMlIh\|ryPLh?=	M3\2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e1NFkxLz5{M{O3OVA6ODxxYU6=
A431	MmrySpVv[3Srb36gZZN{[Xl?		M2nXbVYxKG2rboO=	M4T4O2lvcGmkaYTpc44hd2ZiRVfGVkBqdiCqdX3hckBCPDNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhTUeILXnu[JVk\WRidInyc5NqdmVicHjvd5Bpd3K7bHH0bY9vKGmwY4XiZZRm\CCob4KgOlAhdWmwczDwdolweiC2bzDFS2Yu[WO2aY\heIlwdiCvZXHzeZJm\CBzMDDtbY5{KGK7IFXMTXNCNCCLQ{WwJF0hOS5{IN88UU4>	NVnZNZo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0N\|QyOzlpPkKzOFM1OTN7PD;hQi=>
A431	NV;UWm53TnWwY4Tpc44h[XO\|YYm=		MomxOlAhdWmwcx?=	MoLtTY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KEWOSWPBMEBKSzVyIE2gNU4zKM7:TT6=	NIjjTIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkezPVA6OCd-MkK3N\|kxQTB:L3G+
H9	NGDWeXRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXm3NkBpenN?	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEh7IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCLQ{WwJF0hOS5\|IN88UU4>	MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3OUm1N\|IoRjJ4NUm5OVMzRC:jPh?=
PC9	MmHtSpVv[3Srb36gZZN{[Xl?		MWmyOEBpenN?	NXHpZ3E{UW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OCB;IEGuN\|Yh\|ryPLh?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl6MEKxPEc,OjJ7OECyNVg9N2F-
SK-BR-3	NESxfY9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			M1vndmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utRnIuOyClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVAhRSBzLkW2JO69VS5?	Mm\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
LXFA 289L	NVewOXZOS3m2b4TvfIlkcXS7IHHzd4F6		NVzPbHlVPCCmYYnz	NETvOotEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[DIEK4PWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMT63PEDPxE1w	Mk\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
SCC15	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOFQ{G1JINmdGy\|LDDJR\|UxKD1iMT65OEDPxE1w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
Jurkat	NYXUR\|dPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml[2NlQhcHK\|	Ml7YS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTpVzc2G2IHPlcIx{KGGodHXyJFI1KGi{czygTWM2OCB;IEKg{txONg>?	NEjpWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G3PFczOid-MUexO\|g4OjJ:L3G+
erythroleukemia cell	M4[yc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MX:yOEBpenN?	MVnHdo94fGhiaX7obYJqfGmxbjDv[kBLSUt{IG[2NVdHKG23dHHueEBmgHC{ZYPzbY5oKGi3bXHuJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	NIX2d3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G3PFczOid-MUexO\|g4OjJ:L3G+
erythroleukemia cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmS5NlQhcHK\|	M3HFemdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJIVzgXSqcn;s[ZVs\W2rYTDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	M1[4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
NCI-H1993	NVG4e\|dmS3m2b4TvfIlkcXS7IHHzd4F6		MlnoOFghcHK\|	MlrjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUmzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{LkC0N{DPxE1w	NYLaSWR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
HT-29	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnH0O\|IhcHK\|	Moj6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjD1coRmeiCwb4Ltc5hq[SClb37kbZRqd26\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB{Lkm4JO69VS5?	MlniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
PANC1	NGTxSVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mkf3O\|IhcHK\|	MXzHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQRW5EOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUA{NjFizszNMi=>	NYnTU4c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OFc3QTBpPkK2OVQ4PjlyPD;hQi=>
SCC25	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			Mn\VRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVQ1OyOUBk\WyuczygTWM2OCB;IEOuN\|Qh\|ryPLh?=	M4fGc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
NCI-H358	M4Lv[GFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2LT[\|Q5KGi{cx?=	M2PWRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{PThiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSClY3u4JIF{e2G7LDDJR\|UxKD1iMz65NUDPxE1w	NVr1TGlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|Q5QDdpPkK3NlM1QDh5PD;hQi=>
COS7	NIrJTXhHfW6ldHnvckBie3OjeR?=			MVXJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiVk[xO2YhdXW2YX70JIV5eHKnc4Pl[EBqdiCFT2O3JINmdGy\|LDDJR\|UxKD1iNDFOwG0v	M4LzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
L3.6PL	MlnRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWfuZXZ2PzJiaILz	NF7BSGlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBNOy54UFygZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFSz24JIF{e2G7LDDJR\|UxKD1iNDFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV2N{[5NEc,OjZ3NEe2PVA9N2F-
HT-29	NXLhSG1ESW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVzPeosxPzJiaILz	M1;YfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36geY5l\XJiaInwc5hq[SClb37kbZRqd26\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB2LkO3JO69VS5?	MnjLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
OVCAR3	NF7qc3FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUPnSI1oPzJiaILz	NU\ZNWVZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDPWmNCWjNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA1NjZizszNMi=>	M1qxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
Calu3	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIT2UW84OiCqcoO=	NFW0NphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPhcJU{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKgZox2\SCjc4PhfUwhUUN3MDC9JFQvPyEQvF2u	NHX6b2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
hematopoietic progenitor cell	M1f6[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NUfYeWpkT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSlHLNkBXPjF5RjDteZRidnRiZYjwdoV{e2mwZzDo[Y1ifG:yb3nleIlkKHC{b3flcol1d3JiY3XscJMhcXOxbHH0[YQh\nKxbTDwc4x6[3m2aHXtbYEhfmW{YTDwZZRq\W62IHL5JINwdG:weTDmc5JucW6pIHHzd4F6NCCLQ{WwJF0hPSEQvF2u	NUPU[2UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexO\|g4OjJpPkG3NVc5PzJ{PD;hQi=>
KB	Ml;3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIf5RWk1QCCqcoO=	MoHBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQjDj[YxteyCneIDy[ZN{cW6pIFXHSnIh[W6mIGPyZ{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gOUDPxE1w	Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzOEi2NlAoRjJ4MUi4OlIxRC:jPh?=
N87	MoDmSpVv[3Srb36gZZN{[Xl?			M3z3XmlvcGmkaYTpc44hd2ZiRYLiRlIhcW62cnHj[YxtfWyjcjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTki3JINmdGy\|IHL5JGVNUVODLDDJR\|UxKD1iNT6yJO69VS5?	NETsZ2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OlY2PSd-MkCzOFY3PTV:L3G+
NCI-H1975	MlrMR5l1d3SxeHnjbZR6KGG\|c3H5		NILvdHY4OiCqcoO=	NXq0dGlbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIV5eHKnc4PpcochTUeIUjDMPFU5Wi:WN{mwUUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuOVEh\|ryPLh?=	NX;PU4hNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVEyOjNpPkK0OFEyOTJ\|PD;hQi=>
MRC5	NYLYWFJ7SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4LRV\|czKGi{cx?=	Mor4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPUlO1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iNT64JO69VS5?	M3PQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
HepG2	M4ftWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MYW0PEBpenN?	NW[3d45GSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOU45KM7:TT6=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh7NkewPEc,OjZ6OU[3NFg9N2F-
NCI-H358	M4D1U2FvfGmycn;sbYZmemG2aY\lJIF{e2G7			MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|U5KGOnbHzzJIFnfGW{IHjyd{BjgSCDVGCgZ49vfGWwdDDhd5NigSxiSVO1NEA:KDZizszNMi=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
A549	MkXlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgeoli[mynIHPlcIx{KGGodHXyJFQ5KGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPi5{NjFOwG0v	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh5OUOxOEc,OjZ6N{mzNVQ9N2F-
LNCAP	Mn\4R5l1d3SxeHnjbZR6KGG\|c3H5		NV\USZcxPCCmYYnz	NHXXOpVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA3NjZ\|IN88UU4>	Mo\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
MIAPaCa	M1jRZ2Z2dmO2aX;uJIF{e2G7			NWPtfJRGUW6qaXLpeIlwdiCxZjDFVmJjOiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUmDUHHDZUBk\WyuczDifUBGVEmVQTygTWM2OCB;IE[uO\|Mh\|ryPLh?=	MorJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6MUe1NlMoRjJyOEG3OVI{RC:jPh?=
NCI-H358	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NYqwfnl{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDN3ODDj[YxteyCjc4Pld5Nm\CCjczD2bYFjdGViY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA3Njh3IN88UU4>	NUmwXVdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4O\|k{OTRpPkK2PFc6OzF2PD;hQi=>
NCI-H1975	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3vRdFczKGi{cx?=	Mk[3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMh\XiycnXzd4lv\yCHR1\SJHQ4QTCPIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPi57IN88UU4>	M1zMPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUizO\|QzLz5{NEG4N\|c1OjxxYU6=
NCI-H1975	MmnBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{DOR\|czKGi{cx?=	M4\hdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZJme2m\|dHHueEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEeuNFYh\|ryPLh?=	NIDpXGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2OVk3QSd-MkS1OlU6Pjl:L3G+
A549	NELadVFEgXSxdH;4bYNqfHliYYPzZZk>		NYDpVlRiPDhiaILz	M1Pk[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFcvODl7IN88UU4>	NV7tTXNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
A549	MorIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWe5UVZ6PDhiaILz	NFLXd\|JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBk[2t6IHHzd4F6NCCLQ{WwJF0hPy5\|NTFOwG0v	M2DHfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkO0PFg4Lz5{N{KzOFg5PzxxYU6=
NCI-H1975	M3Xxd2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NXvPeVBKPDhiaILz	M3iwOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz60PVgh\|ryPLh?=	MlyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
HCC827	M2i5XGFvfGmycn;sbYZmemG2aY\lJIF{e2G7			MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFQ{iyO{Bk\WyuczDh[pRmeiCqcoOgZpkhSVSSIHPvcpRmdnRiYYPzZZktKEmFNUCgQUA4NjVizszNMi=>	M{KxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
A549	NXG4eHZCSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYG3NkBpenN?	NHjIZXlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36geY5l\XJibn;ycY95cWFiY3;u[Il1cW:wczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iNz61PUDPxE1w	MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
BxPC3	NUPwZWE6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M{DnS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQojQR\|Mh[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hPy54IN88UU4>	NES0S4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
NCI-H1975	NEPQcGJHfW6ldHnvckBie3OjeR?=		MknwNkBpenN?	M1j2[GlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hPy54IN88UU4>	M{XyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUOwPVk1Lz5{M{mzNFk6PDxxYU6=
PCI35	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX:3NkBpenN?	MnTUS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGNKOzViY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUy16IHHzd4F6NCCLQ{WwJF0hPy55IN88UU4>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV2N{[5NEc,OjZ3NEe2PVA9N2F-
WM266.4	M{\WNmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYWzV3dMOjRiaILz	M1;SZWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gPE4xQSEQvF2u	M365S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUi1PVU4Lz5{Mkm4OVk2PzxxYU6=
WM266.4	NUH3TVUyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkTwNlQhcHK\|	MXnHdo94fGhiaX7obYJqfGmxbjDpckBpfW2jbjDXUVI3Pi52IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRicnXkeYN1cW:wIHHzd4F6NCCJSUWwJF0hQC5zMjFOwG0v	Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OEW5OlIoRjJ{OUi1PVYzRC:jPh?=
WM266.4	M1LPc2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NX32UYR1OjRiaILz	MkP1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCZTUK2Ok41KGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTC4MlE1KM7:TT6=	MofkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{M{i4OFEoRjJ5MkO4PFQyRC:jPh?=
H460	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NF\xRVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hQC5{IN88UU4>	M1PtSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
OVXF 899L	NHfIUZBEgXSxdH;4bYNqfHliYYPzZZk>		MXW0JIRigXN?	MkL6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZZTiB6OUnMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDhwN{eg{txONg>?	NX7KelJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
MCF7	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M{jzWFI1KGi{cx?=	M4jE[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iOD65O{DPxE1w	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl6NUm1O{c,OjJ7OEW5OVc9N2F-
NCI-H1975	M3PFbWZ2dmO2aX;uJIF{e2G7		M1PJUVIhcHK\|	Mm\rTY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboSgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgZYZ1\XJiMjDodpMh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUA6KM7:TT6=	M3\3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
H1975	NEn4T3ZHfW6ldHnvckBie3OjeR?=		MmD4NkBpenN?	NV;aNpp[UW6qaXLpeIlwdiCxZjDFS2ZTKFR5OUDNM2w5PTiUIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGgyQTd3IHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzMDDtbY5{KGK7IIPhcoR4cWOqIFXMTXNCNCCLQ{WwJF0hQS5yMEOg{txONg>?	NH;OeJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4O\|c{OCd-MkiyPFc4OzB:L3G+
A549	NEHVe5FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NUfVXZlmPzJiaILz	M3ryWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjD1coRmeiCqeYDvfIliKGOxbnTpeIlwdnNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDlwMTFOwG0v	M2LoPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[4NFQ1Lz5{NUS2PFA1PDxxYU6=
H460	M2nv[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmHsO\|IhcHK\|	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTC5MlUh\|ryPLh?=	MkHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MUW4OVYoRjJ3MkG1PFU3RC:jPh?=
PC9-DRH	MXTGeY5kfGmxbjDhd5NigQ>?		NGnwdpQzKGi{cx?=	NWPZcmlGUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbHX0bY9vN1R5OUDNJI12fGGwdDDheZRweGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQS2GUligZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTC5Mlch\|ryPLh?=	MnPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
PC9-DRH	MXTGeY5kfGmxbjDhd5NigQ>?		NHXVSYozKGi{cx?=	NHnPe5JKdmirYnn0bY9vKG:oIFXHSnIhXDd7MF2v[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFCFOT3EVmgh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTC5Mlc{PiEQvF2u	NVzrPYdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFc4OzBpPkK4Nlg4PzNyPD;hQi=>
U937	NUTYfJI1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFq5S4Y4OiCqcoO=	M33EOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{IHLseYUh[XO\|YYmsJGlEPTBiPTC5Mlkh\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
PAXF 546L	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		NGjORWU1KGSjeYO=	MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQRXhHKDV2NlygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOTBizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
RXF 486L	M{eze2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NUnkWG9KPCCmYYnz	NYCwTWVwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWliIIES4Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMUCg{txONg>?	NW\pOVNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
CAL27	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NWnXS2liSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDRWwzPyClZXzsd{whUUN3MDC9JFExNjF3IN88UU4>	NIjPZpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SKHEP1	NFzm[JFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MlTVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVS1jFVFEh[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hOTBwM{eg{txONg>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF2M{e3PEc,OjBzNEO3O\|g9N2F-
MDA-MB-468	MlzyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MlLkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{NCCLQ{WwJF0hOTFwNDFOwG0v	NEXzVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SF539	NI\G[nNHfW6ldHnvckBie3OjeR?=		MWe2NEBucW6\|	MlXwTY5pcWKrdHnvckBw\iCSRFfGMWJDNWmwZIXj[YQhWESJRmKgZoV1[SCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hW0Z3M{mgZ4VtdHNib4\ldoV5eHKnc4PpcochWESJRmKgZoV1[SCycnX0doVifGWmIH\vdkA3OCCvaX7zJJBzcW:{IITvJHBFT0ZvQlKgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDwbI9{eGixdInyc5NqdmViRVzJV2Eh[3m2b3Lsc5Qh[W6jbInzbZMtKEmFNUCgQUAyOi5{IN88UU4>	M4\oZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e1NFkxLz5{M{O3OVA6ODxxYU6=
SF539	NGTKcY9HfW6ldHnvckBie3OjeR?=		MXe2NEBucW6\|	Mk\QTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFiaX6gbJVu[W5iU1[1N\|kh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDQSGdHWi2EQj3pcoR2[2WmIIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdiCrbnP1ZoF1\WRiZn;yJFYxKG2rboOgdJJqd3JidH:gSWdHNWGldHn2ZZRqd25ibXXhd5Vz\WRiMUCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDF{LkKg{txONg>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR\|NEGzPUc,OjN2M{SxN\|k9N2F-
SF539	MUXGeY5kfGmxbjDhd5NigQ>?		MkG3OlAhdWmwcx?=	MnfYTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFiaX6gbJVu[W5iU1[1N\|kh[2WubIOgdJJmfHKnYYTl[EBnd3JiNkCgcYlveyCvZXHzeZJm\CCjZoTldkAyKGi{IHL5JGVNUVODLDDJR\|UxKD1iMUKuNkDPxE1w	MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5M{mwPVAoRjJ{N{O5NFkxRC:jPh?=
A498	M2jYZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkLpOFghcHK\|	NEizNllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGyMlUh\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB3N{C0Nkc,OjlyNUewOFI9N2F-
NCI-H661	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		MWC0JJRwKDViZHH5dy=>	NUjPdYZsS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi2OlEh[2WubIOgZYZ1\XJiNDD0c{A2KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOTJwN{Gg{txONg>?	NUTnXlNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
BT474	NUC3V2tNSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoT2O\|IhcHK\|	MoH0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEVES3OEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{IHLseYUh[XO\|YYmsJGlEPTBiPTCxN{DPxE1w	M3rlOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
BXF T24	MYrDfZRwfG:6aXPpeJkh[XO\|YYm=		M3\pUlQh\GG7cx?=	MnrJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRnhHKFR{NDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyOy57IN88UU4>	NGSyb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
CXF 269L	M4f2TmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVq0JIRigXN?	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDXGYhOjZ7TDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyPiEQvF2u	NXPMUJdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
HEK293	NHi2[ldHfW6ldHnvckBie3OjeR?=		MWKyJI1qdnN?	M1rueWlvcGmkaYTpc44hd2ZiaIXtZY4hV0OWMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHWydHHr[UBw\iCDU2CrJIFnfGW{IEKgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCxOk4zKM7:TT6=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ\|MEm4OUc,Ojh{M{C5PFU9N2F-
PC3M	M4P0eWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGn5RpE1KGSjeYO=	NFP6W2xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzOPIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFE4NjJizszNMi=>	NWrH[mpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
A549	MnfXRY51cWOjbnPldkBie3OjeR?=		NVTvVVVYQTZiaILz	MWXBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgPVYhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE4NjN{IN88UU4>	NH;3[WM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0PVg1OSd-Mkm1OFk5PDF:L3G+
LXFL 529L	MYLDfZRwfG:6aXPpeJkh[XO\|YYm=		NIGyV\|g1KGSjeYO=	M1rtOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkxiNUK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzNz60JO69VS5?	NHjDPVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
FADU	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NVzNS2hmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGRWRWKGOnbHzzMEBKSzVyIE2gNVgh\|ryPLh?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
LNCAP	NXe4Vpk1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyQQ1HQJINmdGy\|LDDJR\|UxKD1iMUiuN\|Uh\|ryPLh?=	Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
LO2	NFXSPZpEgXSxdH;4bYNqfHliYYPzZZk>		MkP3OFghcHK\|	NY\Y[nVPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE9{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAyQC53IN88UU4>	MmPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6OU[3NFgoRjJ4OEm2O\|A5RC:jPh?=
MEXF 276L	MYPDfZRwfG:6aXPpeJkh[XO\|YYm=		MWC0JIRigXN?	M2PjcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GYEZiMke2UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSBzOD62JO69VS5?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
DU145	MmnmR5l1d3SxeHnjbZR6KGG\|c3H5		MYG0JJRwKDViZHH5dy=>	MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0JJRwKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzOT60JO69VS5?	M3vnU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
MCF7	MlPvRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2H5S\|Q5KGi{cx?=	Mn20RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{MDFOwG0v	NHvObmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC0O\|QyOCd-M{CwOFc1OTB:L3G+
Saos2	Mne1R5l1d3SxeHnjbZR6KGG\|c3H5		MYq0JIRigXN?	NYjDTFE1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW2Gxc{KgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOjFizszNMi=>	M4rPS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
HEK293	Mn7RSpVv[3Srb36gZZN{[Xl?			NH\ySllKdmirYnn0bY9vKG:oIHj1cYFvKGyrdnXyJG9CXFBzQkGg[ZhxemW\|c3XkJIlvKEiHS{K5N{BHdHBvSX6gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEVzNz3i[ZRiTyC3cIThb4Uh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFIyKM7:TT6=	Ml\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293	M3HVXWZ2dmO2aX;uJIF{e2G7			MoTLTY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROUJzIHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGOTdvYnX0ZWchfXC2YXvlJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGtqKD1iMkGg{txONg>?	M1PCN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSxNFY5Lz5{MkW0NVA3QDxxYU6=
A549	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWm3NkBpenN?	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJzLkOg{txONg>?	NXHoXnFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PFY2ODlpPkK4PFg3PTB7PD;hQi=>
H460/Vbl	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=		M3vzU\|czKGi{cx?=	MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxN1[kbDDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOjFwNTFOwG0v	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJzNUi1Okc,OjV{MUW4OVY9N2F-
UXF 1138L	M1jkSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4rLVVQh\GG7cx?=	MlLyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWXhHKDFzM{jMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDJ2LkWg{txONg>?	M1f5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
MAXF 401NL	NIrqWmREgXSxdH;4bYNqfHliYYPzZZk>		MnXiOEBl[Xm\|	NV7Ee4pvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUG[RjC0NFFPVCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCyOUDPxE1w	MoXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
HepG2	NXqxW5p1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MljMOFghcHK\|	NX;tdFJOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNlUh\|ryPLh?=	Mn\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNEe0NVAoRjNyMES3OFExRC:jPh?=
HepG2	NYLrWHFJS3m2b4TvfIlkcXS7IHHzd4F6		NFzxSngzPCCqcoO=	MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpktKEmFNUCgQUAzPSEQvF2u	M3W2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEi3NVI4Lz5{OES4O\|EzPzxxYU6=
HuH7	NGjuU\|dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH3OdG01QCCqcoO=	MoXlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKdVi3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{NTFOwG0v	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB3N{C0Nkc,OjlyNUewOFI9N2F-
A498	NHfIZ4RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkT4OFghcHK\|	M1;lOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO\|aX7nJGVITlJiYX7kJHNz[yCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOjVwNjFOwG0v	NF7oNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG4PFYzOCd-Mk[xPFg3OjB:L3G+
MEXF 1341L	M3jOPGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mn7qOEBl[Xm\|	M4i2OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GYEZiMUO0NWwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iM{CuNUDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
MDA-MB-231	NF\ROHFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWixS\|d4PzJiaILz	NGD3WoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzBwMUKg{txONg>?	NV7sWWR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlM{QDNpPkK4PVI{Ozh\|PD;hQi=>
PXF 1752L	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		MoDxOEBl[Xm\|	NIDmWHREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRYEZiMUe1Nmwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iM{GuOkDPxE1w	MlX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
A549	MknjR5l1d3SxeHnjbZR6KGG\|c3H5		NEDqd4U1KHSxIEWg[IF6ew>?	NUP6c5dHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1KHSxIEWg[IF6eyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCzN{4xOyEQvF2u	NVfMTZhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
MDA-MB-231	NHPDSHpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoPjOFghcHK\|	NGC0TIxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzNwNE[g{txONg>?	NXPLNFBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlM{QDNpPkK4PVI{Ozh\|PD;hQi=>
MDA231	M4\kSGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Ml\COEBl[Xm\|	NWrNV4l4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDMkOxJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDN2LkWg{txONg>?	NYHPe4FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
LXFL 1121L	M1H0UWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEDkT\|Y1KGSjeYO=	NGLqUHZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNYE[OIEGxNlFNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEO0MlYh\|ryPLh?=	M4T1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
PXF 698L	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		NX;hPZBnPCCmYYnz	MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQXGYhPjl6TDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA{Pi52IN88UU4>	MljIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
PC3	MV7DfZRwfG:6aXPpeJkh[XO\|YYm=		NVTkRYFTPCC2bzC1JIRigXN?	NFKxb5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOEB1dyB3IHThfZMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iM{[uO\|Yh\|ryPLh?=	M4C0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
HEK293	M3riN2Z2dmO2aX;uJIF{e2G7		MlrhOUBucW6\|	NVLiXGZHUW6qaXLpeIlwdiCxZjDoeY1idiCuaY\ldkBQSVSSMVKzJIV5eHKnc4Pl[EBqdiCKRVuyPVMhTmyyLVnuJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCdM1jdSVE4NWKndHHHJJVxfGGtZTDpcoN2[mG2ZXSg[o9zKDVibXnud{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcSB;IESxJO69VSxiSVO1NEA:KDR2IN88UU4>	M2rXV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSxNFY5Lz5{MkW0NVA3QDxxYU6=
RXF 393NL	NYTQZWhuS3m2b4TvfIlkcXS7IHHzd4F6		MkO1OEBl[Xm\|	M3HjZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJZTiB\|OUPOUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB2NT62JO69VS5?	MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
LIXF 575L	MlzsR5l1d3SxeHnjbZR6KGG\|c3H5		MmnoOEBl[Xm\|	MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMTXhHKDV5NVygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hPDdwMjFOwG0v	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
NCI-H23	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		MXm0OkBpenN?	M37zbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES2JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0PU4{KM7:TT6=	NVXPSIFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxN\|gxOjdpPkK5NVM5ODJ5PD;hQi=>
polycythemia vera hematopoietic progenitor cell	NVf0fGlkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXzwXlRvPSC3TR?=		NX21WolqT3Kxd4ToJIlvcGmkaYTpc44hd2ZiSlHLNkBXPjF5RjDteZRidnRiZYjwdoV{e2mwZzDoeY1idiCyb3z5Z5l1cGWvaXGgeoVz[SCqZX3heI9xd2mndHnjJJBzd2enbnn0c5Ih[2WubIOgZZQhPSC3TTDifUBmenm2aILvbYQh[nW{c4St[o9zdWmwZzD1col1KGG\|c3H5MEBPXUyOIE2gUnVNVCEQvF2u	M{DEelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUe4O\|IzLz5zN{G3PFczOjxxYU6=
A431	NVPMNpNGTnWwY4Tpc44h[XO\|YYm=		M1:wc\|EhcHK\|	M{XCe2lvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSTR\|MTDj[YxteyCycnX0doVifGWmIH\vdkAyKGi{czDmc4xtd3enZDDifUBGT0Zvc4TpcZVt[XSrb36gZpkhcW2vdX7vZoxwfCCjbnHsfZNqeyxiTmXMUEA:KE6XTFyg{txONg>?	NVLpOJJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
PC9	Mle3R5l1d3SxeHnjbZR6KGG\|c3H5	NVjTTmZmOC5yMEGgeI8hOTBidV2=	MlXVPVYhcHK\|	MojJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM6KGOnbHzzJIV5eHKnc4PpcochPzR4LUe1NEB{\XG3ZX7j[UBl\WyndHXkJGVITlJiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYYSgNE4xODFidH:gNVAhfU1iYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDOWWxNKD1iTmXMUEDPxE1w	NY\1c\|BPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
NCI-H1975	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=	MnPrNE4xODFidH:gNVAhfU1?	MnH0PVYhcHK\|	MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNJIFv\CCOOEW4VkBufXSjboSgZZQhOC5yMEGgeI8hOTBidV2gZYZ1\XJiOU[gbJJ{KGK7IHPlcIwhfGm2ZYKt[4xwKGG\|c3H5MEBPXUyOIE2gUnVNVCEQvF2u	M2rRb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkKyO\|M{Lz5{MEKyNlc{OzxxYU6=
Huh7.5	M3;DdGFvfGm4aYLhcEBie3OjeR?=		NY\aOlhwOzBibXnudy=>	MWXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDI[ZBifGm2aYOgR{B3cXK3czDKOk9LTkhiaX7m[YN1\WRiaX6gbJVu[W5iSIXoO{42KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gTGNXKHKncHzpZ4F1cW:wIIDy[ZRz\WG2ZXSg[o9zKDNyIH3pcpMh\m:ubH;3[YQh[nliaX7m[YN1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDkfYUh[mG\|ZXSg[ox2d3Knc3PlcoNmKGG\|c3H5MEBC[3Srdnn0fUA:KE6XTFyg{txONg>?	NVrYdYUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5NlUzODhpPkK2PVI2OjB6PD;hQi=>
A673	MmPudWhVWyCjc4PhfS=>			MnjTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHNuIF7VUGwhRSCQVVzMJO69VS5?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NG\SV4lyUFSVIHHzd4F6			NG\pVo1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	NHHh[\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NWHNSXB2eUiWUzDhd5NigQ>?			NWq4d2QzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	NXjNTZhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MV;xTHRUKGG\|c3H5			MkXLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|LDDOWWxNKD1iTmXMUEDPxE1w	NEfWUnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NXK3Vo9TeUiWUzDhd5NigQ>?			Ml7FdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	NI[0OJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	MoDNdWhVWyCjc4PhfS=>			NEHxc5pyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	M3;iXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NU\Ie4V3eUiWUzDhd5NigQ>?			MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	NYrBNpl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MofrdWhVWyCjc4PhfS=>			MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0{PyClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	NXjZRng2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	Moq2dWhVWyCjc4PhfS=>			NFz3bZZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MV;xTHRUKGG\|c3H5			M2DFTJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJMtKE6XTFygQUBPXUyOIN88UU4>	NID3WnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MY\xTHRUKGG\|c3H5			MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	M3HFclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	Mo\FdWhVWyCjc4PhfS=>			NIrod29yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsd{whVlWOTDC9JG5WVExizszNMi=>	NWL6NIhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NHLWeINyUFSVIHHzd4F6			MnTMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIOsJG5WVExiPTDOWWxNKM7:TT6=	MkPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MlPndWhVWyCjc4PhfS=>			NVnhcZZ6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzzMEBPXUyOIE2gUnVNVCEQvF2u	NIL5e5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MnvpdWhVWyCjc4PhfS=>			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[YxteyxiTmXMUEA:KE6XTFyg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MmHJdWhVWyCjc4PhfS=>			NUi0Rm56eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\WyuczygUnVNVCB;IF7VUGwh\|ryPLh?=	MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MUfxTHRUKGG\|c3H5			M2nDV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJMtKE6XTFygQUBPXUyOIN88UU4>	MnHIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HCC827	MX;BdI9xfG:\|aYOgZZN{[Xl?	NID0UmoyKHWP	MVGyOEBpenN?	MYjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDheEAyKHWPIHHmeIVzKDJ2IHjyd{B2e2mwZzDwdo9xcWSrdX2gbY9lcWSnIHL5JIZtd3diY4n0c41mfHK7LDDOWWxNKD1iTmXMUEDPxE1w	NIS0WmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
NCI-H1648	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NVTQXmhUUUN3MDC9JFAvODRyMEKg{txO	NEj1eVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-12	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MmPCTWM2OCB;IECuNFU1PDFizszN	MnTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ECC12	NXniVYJ3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NULVVldGUUN3MDC9JFAvODhyNUKg{txO	NFrQZ5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BB30-HNC	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NUTESnZwUUN3MDC9JFAvOTR5NkWg{txO	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB996-RCC	NFHneJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NYLVV5BpUUN3MDC9JFAvPDBzNkGg{txO	NVO2[md6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-24	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MmLiTWM2OCB;IECuOVk1PDNizszN	NEPnN3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
LC-1F	NIrSW21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M362RWlEPTBiPTCwMlYxPjN{IN88US=>	M3TzNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TK10	NF7nR5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NGfHUYNKSzVyIE2gNE45PTh5ODFOwG0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
A388	NWXpb41yT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M2XLdWlEPTBiPTCxMlA6OzhizszN	M4n1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
EKVX	NVzaOVY2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NHfhSYlKSzVyIE2gNU4yOjN3NDFOwG0>	MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-9	NFOwSFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MkDoTWM2OCB;IEGuNlI2OTFizszN	MlnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-1	NFy0VnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYDJR\|UxKD1iMT60NFQ5KM7:TR?=	NI\MWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MOLT-16	NGKzc2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NE\6XmpKSzVyIE2gNU46Ojl{NTFOwG0>	NYrPUlRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-6	MoTCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NVGw[3VrUUN3MDC9JFIvPTZ5ODFOwG0>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
697	NFfWTFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NFjHUWhKSzVyIE2gNk43PTNyNTFOwG0>	NXr5SoNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
A253	MnTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MUHJR\|UxKD1iMj63OVE3KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
OS-RC-2	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXTJR\|UxKD1iMj65OFAzOyEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
KS-1	M4O2bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NUT3cldPUUN3MDC9JFIvQTR3NEKg{txO	NVvPUXh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MC116	NI[yO3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M2jud2lEPTBiPTCzMlYzODR7IN88US=>	M2i4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LB2241-RCC	NVPYRmt6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NY\jfVV1UUN3MDC9JFMvQDF5Mkmg{txO	M4K5VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
RL95-2	NYTue3d7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MXXJR\|UxKD1iND6wN\|MzKM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
HCE-T	NGK0TGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYfJR\|UxKD1iND6xNFE5QCEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCCIT	NEfmepRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M2fmTWlEPTBiPTC0MlM5PDl5IN88US=>	NUXQRo5sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
GCIY	M{TnbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYXJR\|UxKD1iND62N\|U{OiEQvF2=	NFnLV289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
LB1047-RCC	NHyySFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1zjUGlEPTBiPTC0Mlk5Ozd7IN88US=>	NVz2Z3lORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
A3-KAW	M1TFc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M2fWfWlEPTBiPTC1MlQ{QTR4IN88US=>	NE\EZ489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-15	NWTtOmR6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NGCwcW5KSzVyIE2gOU41PzJ5IN88US=>	NH3hV\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NOS-1	NIjlZ3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVfJR\|UxKD1iNT60PVM5PiEQvF2=	NYnzd2UxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-16	NGLTUo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MnvLTWM2OCB;IE[uNlU{QDdizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LAMA-84	Ml\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M4\lTGlEPTBiPTC3MlAxPzd{IN88US=>	MkXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-5	NHvlVWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M4nkfGlEPTBiPTC3MlA1OjR5IN88US=>	M{HiUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
HEL	NFToRXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoPwTWM2OCB;IEeuN\|M2PjRizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCI-H209	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NE\BfndKSzVyIE2gPE4xPDRzMjFOwG0>	NFzX[ok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
DJM-1	NGfxfXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MnjoTWM2OCB;IEiuOVI6PjRizszN	NGfhZmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OVCAR-4	NWTl[nZUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NW\Nb5hEUUN3MDC9JFgvQDR{MUmg{txO	M3ji[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB17	M4jl[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NGDXUIhKSzVyIE2gPU4zPTl7MTFOwG0>	NX3pS2hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NHTpO4dKSzVyIE2gPU4{PTd5NjFOwG0>	NYXsdI5tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NB5	NX\POodwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NEC3cVdKSzVyIE2gNVAvOjlizszN	M2jMeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
BV-173	M17kVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NIS2XIVKSzVyIE2gNVAvOzJ5MjFOwG0>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MPP-89	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NEfDRmVKSzVyIE2gNVAvPDR{IN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
RPMI-6666	NFX5eFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MmrUTWM2OCB;IEGwMlQ6PjlizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MS-1	MkT5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M3;D[2lEPTBiPTCxNU41PjV6IN88US=>	MoD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ALL-PO	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NH\EW2pKSzVyIE2gNVEvPTF5OTFOwG0>	MnLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB10	NGnkNoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NEf4b2lKSzVyIE2gNVEvPzV6NzFOwG0>	Ml;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB13	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXfJR\|UxKD1iMUGuPVkyPCEQvF2=	NWfu[HRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SCH	NF\QfpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXHJR\|UxKD1iMUKuNVg6OSEQvF2=	Mom1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ES6	M2fVUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M1HEbmlEPTBiPTCxNk41PzVizszN	Moe1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ETK-1	M{TsWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M37M[mlEPTBiPTCxOE4xQDh3IN88US=>	MlLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ES4	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M3L6cWlEPTBiPTCxOE45PDR3IN88US=>	NWK2THpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
K-562	MojRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MULJR\|UxKD1iMUWuPFE1KM7:TR?=	M1\lNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
D-502MG	NHfvcGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MYXJR\|UxKD1iMUeuN\|Q3QCEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LB647-SCLC	M1L6TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M1S0WGlEPTBiPTCxO{44PzJ4IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-10	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Mlq2TWM2OCB;IEG4MlEyOzhizszN	MmrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MZ1-PC	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M4HKdmlEPTBiPTCxPE4{Pzd2IN88US=>	M4HYOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
CTB-1	M{fXcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MVPJR\|UxKD1iMUiuOVA4PSEQvF2=	MlXHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NMC-G1	NF7OfVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NWPKWnhrUUN3MDC9JFE5NjhyMkmg{txO	NVzod3I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
C2BBe1	MoTOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NXy2RYF3UUN3MDC9JFE5Njh4NkSg{txO	MojxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SK-PN-DW	NWT3dmNiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M37YWGlEPTBiPTCxPU42PDh{IN88US=>	NFTo[Ho9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
HCC2157	NVLCc\|BlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MkTuTWM2OCB;IEKwMlM{PjFizszN	MnXuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
Becker	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnPITWM2OCB;IEKwMlM2PDFizszN	Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ST486	NX7lWoFUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MYPJR\|UxKD1iMkCuOFA6OyEQvF2=	NYPzWpRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LC-2-ad	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NH\JOYxKSzVyIE2gNlAvQTZ\|NzFOwG0>	M{H0dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H747	MlviS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MVvJR\|UxKD1iMkGuOVE{QSEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
BE-13	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NFXtWGxKSzVyIE2gNlEvQDF3ODFOwG0>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
no-11	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Mn7nTWM2OCB;IEKxMlkyODZizszN	M{\TRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-8	MlfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MYrJR\|UxKD1iMkKuOlMyQCEQvF2=	NX21U4VvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NB6	NIPDN5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NEfaN\|NKSzVyIE2gNlIvQDNyMzFOwG0>	MlHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BB65-RCC	M1;iemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NVrwPG1vUUN3MDC9JFIzNjl4MkOg{txO	M4G0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SK-UT-1	NVLtSJQxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MV\JR\|UxKD1iMkOuNVQ6PyEQvF2=	NFPCTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
D-392MG	NX;PbFJiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MXnJR\|UxKD1iMkSuNlk{PCEQvF2=	MmLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
JVM-2	NX\pUllFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NIHURopKSzVyIE2gNlQvPTN\|MzFOwG0>	MoHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SW954	MlHiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NXX0e2JwUUN3MDC9JFI1NjV7MU[g{txO	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
QIMR-WIL	NEjJVZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MVPJR\|UxKD1iMkWuNVk4OyEQvF2=	MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MEG-01	M1;pPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3;rPWlEPTBiPTCyOU46ODF4IN88US=>	Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
A101D	Mk\ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NWnCZZFHUUN3MDC9JFI5NjdzM{mg{txO	NX:0VlQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LB831-BLC	NWXMfppnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M3fWZ2lEPTBiPTCzNE41ODB2IN88US=>	MonuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
KGN	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MYnJR\|UxKD1iM{CuPFY3OSEQvF2=	NVG0ZldXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HC-1	NUjiZ2M3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NF7B[mtKSzVyIE2gN\|EvOzVyODFOwG0>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
CP66-MEL	NX:wOmgzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M2Ln[WlEPTBiPTCzNU45OzZ4IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
D-542MG	NYTQcIhKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NGDoT29KSzVyIE2gN\|IvPDN\|NzFOwG0>	M4Lhd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LS-513	M3LTdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MknJTWM2OCB;IEOzMlQ5PDRizszN	NWXnVnpORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
DOHH-2	M3vDUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MW\JR\|UxKD1iM{OuOlU5QSEQvF2=	M{X1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB69	NHTCN\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MX;JR\|UxKD1iM{OuPVIxPiEQvF2=	M4HzdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SW962	NWHlZYJCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MUfJR\|UxKD1iM{WuO\|IyPyEQvF2=	MnrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
J-RT3-T3-5	M2jUSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NF3mU45KSzVyIE2gN\|YvODd{NDFOwG0>	MnLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MONO-MAC-6	NXzOWYVbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M2XYWWlEPTBiPTCzOk42OzV7IN88US=>	M2n5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
MLMA	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MUDJR\|UxKD1iM{iuOlUzKM7:TR?=	MnfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HOP-62	M33Mbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHv2[FBKSzVyIE2gN\|kvOTd4NTFOwG0>	MmHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LP-1	NWXWRlFvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MnjvTWM2OCB;IEO5MlQ1OTVizszN	Mo\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ONS-76	NUnuN5hkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MV;JR\|UxKD1iM{muPVE2OiEQvF2=	M2fB[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KNS-42	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MnPPTWM2OCB;IESwMlA2OzFizszN	NY\td4dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCI-H1581	NEDPb3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MojUTWM2OCB;IESxMlE5PDJizszN	NXLj[3ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
DSH1	NFzwSFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			Mkj1TWM2OCB;IESyMlQxPyEQvF2=	M17aPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H1355	NFz6OZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1fuUGlEPTBiPTC0Nk45OzlizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
D-247MG	NHHNXINIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NWTQUIl6UUN3MDC9JFQ2NjdzOTFOwG0>	MmPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MC-CAR	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MlHLTWM2OCB;IES1Mlk3QTFizszN	NXzGWXRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-1	NGjVW4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MlPFTWM2OCB;IES3MlU3OjRizszN	NIHqPFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
GI-ME-N	NE\rXmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NFfQXnBKSzVyIE2gOFgvOTN6NDFOwG0>	NGDlWYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
BT-474	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			Mmm2TWM2OCB;IES4MlE4OzhizszN	NVy0eIY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	NEHKRohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoL4TWM2OCB;IES4Mlc2PjNizszN	NGe5cGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Met / Met / p-Axl / Axl / pERK / ERK / pEGFR / EGFR / p-STAT3 / STAT3 / p-Akt / Akt; PubMed: 28604685 Nat Neurosci (b) Patient derived primary GBM neurospheres (GBM9) were exposure to erlotinib (1µM) for the indicated times followed by Western blot with the indicated antibodies. (c–d) A similar experiment in patient derived GBM neurospheres from two different patients (GBM39 and SK987). (e) U87EGFR cells were treated with erlotinib (1µM) for the indicated times followed by Western blot with the indicated antibodies. (f) Similar experiment was conducted in U87EGFRvIII cells. p-Raf-1 / Raf-1 / p-MEK / MEK; PubMed: 27508092 Am J Cancer Res Cells from both ER and ECR groups were treated with 3 μM erlotinib for 72 h. Cell lysates were used for Western blotting with indicated antibodies. cleaved PARP / PARP; PubMed: 27508092 Am J Cancer Res HCC827 or H1650 cells were treated with DMSO, celecoxib, erlotinib alone, or in combination for 48 h. Western blot analysis showed that cleaved PARP was higher in cells after combination treatment. p27 / pS10-p27 / pT157-p27 / pT187-p27; PubMed: 21045138 Mol Cancer Ther BT-474 and SK-BR-3 cells were treated with erlotinib at 0, 1, or 3 µM for 72 h, after which expression of total p27, p27 phosphorylated at S10 (pS10-p27), pT157-p27, and pT187-p27 was assessed by western blot analysis. β-actin was used as a loading control. Bcl-2 / Bcl-xl / Mcl-1 / Bax / Bak / Bad / Bim EL / PUMA; PubMed: 17927446 PLoS Med Effects of erlotinib treatment on proapoptotic and antiapoptotic proteins in H3255 cells. H3255 cells were treated with different concentrations of erlotinib for 24 h. Cell lysates were examined by immunoblotting using antibodies specific for the indicated proteins.	28604685 27508092 21045138 17927446
Immunofluorescence	Bax / Cyto C; PubMed: 17927446 PLoS Med Erlotinib induces colocalization of BAX and cytochrome c in PC-9 cells undergoing apoptosis. Cells were grown in Lab-Tek II chambers and treated with 100 nM erlotinib or DMSO for 48 h, fixed and immunostained with antibodies against BAX (green) and cytochrome c (red) or with DAPI to detect DNA (blue). Cells were imaged by confocal microscopy. E-cadherin / β-catenin / Vimentin; PubMed: 19825949 Clin Cancer Res SUM149 cells were plated in 3D culture without or with erlotinib for 4 days. Immunofluorescence analysis was performed to detect E-cadherin, β-catenin, and vimentin. Nuclei were visualized with DAPI. EGFR ; PubMed: 27612423 Oncotarget HCC827 (delE746-A750), NCI-H3255 (L858R) and NCI-H1975 (L858R/T790M) cells were treated either with DMSO (control) or with 3 μM erlotinib/200 nM AZD9291 for the indicated time points. Cells were fixed and stained with EGFR antibody (red) and DAPI (blue, DNA dye) as described in the Materials and Methods. Representative images showing decreased EGFR immunofluorescence in erlotinib-sensitive HCC827 and NCI-H3255 cells. AZD9291 also reduced EGFR immunofluorescence even in NCI-H1975 cells. Scale bars, 10 μm.	17927446 19825949 27612423
Growth inhibition assay	Cell viability; PubMed: 30377412 Cancer Cell Int a The MTT assay for PANC-1 viability. Different doses of erlotinib were added to the medium of PANC-1 cells. b LDH release was used to evaluate the cell death in PANC-1 cells in the presence of erlotinib. c The MTT assay for PaCa-2 cells in the presence of erlotinib treatment. d LDH release was used to evaluate the cell death in PaCa-2 cells in the presence of erlotinib.	30377412

In vivo

At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. ^[1] Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate. ^[5]

Protocol

Kinase Assay:^[1]	- Collapse Kinase assays: 96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colonmetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.
Cell Research:^[2]	- Collapse Cell lines: A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 cells Concentrations: 30 nM-20 μM Incubation Time: 72 hours Method: Exponentially growing cells are seeded in 96-well plastic plates and exposed to serial dilutions of erlotinib, pemetrexed, or the combination at a constant concentration ratio of 4:1 in triplicates for 72 h. Cell viability is assayed by cell count and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition is expressed as the percentage of surviving cells in drug-treated versus PBS-treated control cells (which is considered as 100% viability). The IC50 value is the concentration resulting in 50% cell growth inhibition by a 72-h exposure to drug(s) compared with untreated control cells and is calculated by the CalcuSyn software. (Only for Reference)
Animal Research:^[6]	- Collapse Animal Models: Male 5-week-old BALB-nu/nu with HPAC cells Dosages: 50 mg/kg Administration: Oral administration (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.3 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 15% Captisol For best results, use promptly after mixing.	16 mg/mL warmed (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Erlotinib HCl (OSI-744) SDF

Molecular Weight	429.90
Formula	C₂₂H₂₃N₃O₄.HCl
CAS No.	183319-69-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP358774, NSC 718781
Smiles	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04172779	Not yet recruiting	Drug: Erlotinib Hydrochloride	Cirrhosis Liver	University of Texas Southwestern Medical Center	July 2022	Phase 2
NCT03460678	Terminated	Drug: Pemetrexed\|Drug: Erlotinib	Carcinoma Non-Small-Cell Lung	Hikma Pharmaceuticals LLC	February 28 2018	Phase 4
NCT02942095	Active not recruiting	Drug: Ixazomib\|Drug: Erlotinib	Solid Tumors	M.D. Anderson Cancer Center\|Millennium: The Takeda Oncology Company	March 6 2017	Phase 1
NCT02991651	Recruiting	Drug: IRX4204\|Drug: erlotinib	Lung Cancer Nonsmall Cell	Io Therapeutics\|Dartmouth College	May 2016	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether S1023 is suitable for mouse assays?
Answer:
Dissolving S1023 in 15% Captisol is for oral gavage and it's a suspension.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Erlotinib HCl (OSI-744)